المؤلفون: Замятина, А. А., Пересмехина, Т. Г.

مصطلحات موضوعية: ДЕТСКИЙ ВОЗРАСТ, ПОЗНАВАТЕЛЬНЫЕ ПРОЦЕССЫ, ДЕТСКИЕ ИГРЫ, ИГРЫ ДЕТЕЙ, КОМПЬЮТЕРНЫЕ ИГРЫ

وصف الملف: application/pdf

Relation: Психология сегодня : сборник студенческих научных работ. Вып. 4. — Екатеринбург, 2002; Замятина, А. А. Компьютерные игры как вспомогательное средство развития познавательных процессов детской личности / А. А. Замятина, Т. Г. Пересмехина // Психология сегодня : сборник студенческих научных работ. Вып. 4 / Урал. гос. проф.-пед. ун-т, Фак. психологии. - Екатеринбург : УГППУ, 2002. - С. 56-59.; https://elar.rsvpu.ru/handle/123456789/43956

الاتاحة: https://elar.rsvpu.ru/handle/123456789/43956

المؤلفون: Кондратенко Анастасия Борисовна, ФГБОУ ВО «Кубанский государственный университет», Anastasiia B. Kondratenko, Kuban State University, Кондратенко Игорь Сергеевич, Igor S. Kondratenko

المصدر: Modern educational process: psychological and pedagogical support, educational strategies; ; Современный образовательный процесс: психолого-педагогическое сопровождение, воспитательные стратегии

مصطلحات موضوعية: психологическая поддержка, пожилой возраст, детский возраст, самопомощь, горе, особенности проживания утраты, горевание, техники психологической помощи

وصف الملف: text/html

Relation: info:eu-repo/semantics/altIdentifier/isbn/978-5-907830-92-9; https://phsreda.com/e-articles/10658/Action10658-114043.pdf; Боулби Дж. Создание и разрушение эмоциональных связей / Дж. Боулби. – М.: Академический проект, 2004. – 232 с. – EDN QXILLP; Грин Андре. Мертвая мать / Андре Грин // Французская аналитическая академия / под ред. А. Жибо, А.В. Россохина. – СПб.: Питер, 2005.; Шеллински К. Замещающие дети / Кристина Шеллински // Юнгианский анализ. – 2013. – №1. – С. 4–25.; Шутценбергер А.А. Синдром предков / Анн Анселин Шутценбергер // Трансгенерационные связи, семейные тайны, синдром годовщины, передача травм и практическое использование геносоциограммы. – М.: Изд-во Института Психотерапии, 2001. – 252 с.; Cain A.C. On Replacing Child / A.C. Cain, B.S. Cain // Journal of American Academy of Child Psychiatry. 1964. №3.; Porot M. Lenfant de remplacement / M. Porot // Editions Frison-Roche. – 1993/1996.; Poznanski E.O. Journal of Behav / E.O. Poznanski // Pediatrics. 1972. №81 (6).; Sabbadini A. The replacement child. The instance of being someone else / A. Sabbadini // Br. Psychoanalytical Society Bull, 1986.; Моуди Рэймонд. Жизнь после жизни: тетралогия / Рэймонд Моуди, Пол Пэрри, Дайан Аркэнджел; пер. с англ. О. Лисенковой. – М.: КоЛибри; Азбука-Аттикус, 2022. – 592 с.; https://phsreda.com/article/114043/discussion_platform

الاتاحة: https://phsreda.com/article/114043/discussion_platform
https://phsreda.com/files/Books/10658/Cover-10658.jpg?req=114043

المؤلفون: S. A. Shkodkina, I. A. Afonina, С. А. Шкодкина, И. А. Афонина

المصدر: Meditsinskiy sovet = Medical Council; № 19 (2024); 159-166 ; Медицинский Совет; № 19 (2024); 159-166 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: ранний детский возраст, topical corticosteroids, methylprednisolone aceponate, disruption of the epidermal barrier, young children, топические кортикостероиды, метилпреднизолона ацепонат, нарушение эпидермального барьера

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8718/7654; Mortz CG, Andersen KE, Dellgren C, Barington T, Bindslev-Jensen C. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities. Allergy. 2015;70(7):836–845. https://doi.org/10.1111/all.12619.; Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003;361(9352):151–160. https://doi.org/10.1016/S0140-6736(03)12193-9.; Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, FinkWagner A et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. https://doi.org/10.1111/jdv.14891.; Zheng T, Yu J, Oh MH, Zhu Z. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. Allergy Asthma Immunol Res. 2011;3(2):67–73. http://dx.doi.org/10.4168/aair.2011.3.2.67.; Fishbein AB, Mueller K, Kruse L, Boor P, Sheldon S, Zee P, Paller AS. Sleep disturbance in children with moderate/severe atopic dermatitis: A case-control study. J Am Acad Dermatol. 2018;78(2):336–341. https://doi.org/10.1016/j.jaad.2017.08.043.; Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol.1980;92(Suppl.):44–47. https://doi.org/10.2340/00015555924447.; Consensus report of the European Task Force on Atopic Dermatitis. Severity of scoring of atopic dermatitis: the SCORAD index. Dermatology. 1993;186:23–31. https://doi.org/10.1159/000247298.; Vakharia PP, Chopra R, Silverberg JI. Systematic Review of Diagnostic Criteria Used in Atopic Dermatitis Randomized Controlled Trials. Am J Clin Dermatol. 2018;19(1):15–22. https://doi.org/10.1007/s40257-017-0299-4.; Kubanov AA, Namazova-Baranova LS, Khaitov RM, Ilina NI, Alekseeva EA, Ambarchian ET et al. Clinical Practice Guidelines. Atopic dermatitis. Russian Journal of Allergy. 2021;18(3):44–92. (In Russ.) https://doi.org/10.36691/RJA1474.; Wollenberg A, Schnopp C. Evolution of conventional therapy in atopic dermatitis. Immunol Allergy Clin North Am. 2010;30:351–368. https://doi.org/10.1016/j.iac.2010.06.005.; Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. https://doi.org/10.1016/j.jaad.2014.03.023.; Kovaleva YuS, Vedler AA, Kozhevnikova PE. The role of ceramides in preserving the epidermal barrier. Klinicheskaya Dermatologiya i Venerologiya. 2019;18(4):513–518. (In Russ.) https://doi.org/10.17116/klinderma201918041513.; Böhme M, Söderhäll C, Kull I, Bergström A, van Hage M, Wahlgren CF. Filaggrin mutations increase the risk for persistent dry skin and eczema independent of sensitization. J Allergy Clin Immunol. 2012;129(4):1153–1155. https://doi.org/10.1016/j.jaci.2011.11.032.; McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol. 2013;131(2):280–291. http://doi.org/10.1016/j.jaci.2012.12.668.; Weidinger S, Illig T, Baurecht H, Irvine AD, Rodriguez E, Diaz-Lacava A et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol. 2006;118(1):214–219. https://doi.org/10.1016/j.jaci.2006.05.004.; Malajian D, Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine. 2015;73(2):311–318. https://doi.org/10.1016/j.cyto.2014.11.02.; Noval Rivas M, Burton OT, Oettgen HC, Chatila T. IL-4 production by group 2 innate lymphoid cells promotes food allergy by blocking regulatory T-cell function. J Allergy Clin Immunol. 2016;138(3):801–811.e9. https://doi.org/10.1016/j.jaci.2016.02.030.; Cho SH, Strickland I, Tomkinson A, Fehringer AP, Gelfand EW, Leung DY. Preferential binding of Staphylococcus aureus to skin sites of Th2mediated inflammation in a murine model. J Invest Dermatol. 2001;116(5):658–663. https://doi.org/10.1046/j.0022-202x.2001.01331.x.; Kecskes A, Heger-Mahn D, Kuhlmann RK, Lange L. Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal anti-inflammatory activity. J Am Acad Dermatol. 1993;29(4):576–580. https://doi.org/10.1016/0190-9622(93)70224-h.; Mooney E, Rademaker M, Dailey R, Daniel BS, Drummond C, Fischer G et al. Adverse effects of topical corticosteroids in pediatric eczema: Australasian consensus statement. Australas J Dermatol. 2015;56(4):241–251. https://doi.org/10.1111/ajd.12313.; Hong E, Smith S, Fischer G. Evaluation of the atrophogenic potential of topical corticosteroids in pediatric dermatology patients. Pediatr Dermatol. 2011;28(4):393–396. https://doi.org/10.1111/j.15251470.2011.01445.x.; Kravvas G, Gholam K. Use of topical therapies for pediatric psoriasis: A systematic review. Pediatr Dermatol. 2018;35(3):296–302. https://doi.org/10.1111/pde.13422.; Contento M., Cline A., Russo M. Steroid Phobia: A Review of Prevalence, Risk Factors, and Interventions. Am J Clin Dermatol. 2021;22(6):837–851. https://doi.org/10.1007/s40257-021-00623-6.; Hachem M, Gesualdo F, Ricci G, Diociaiuti A, Giraldi L, Ametrano O et al. Topical corticosteroid phobia in parents of pediatric patients with atopic dermatitis: a multicentre survey. Ital J Pediatr. 2017;43(1):22. https://doi.org/10.1186/s13052-017-0330-7.; Fishbein AB, Mueller K, Lor J, Smith P, Paller AS, Kaat A. Systematic review and meta-analysis comparing topical corticosteroids with vehicle/moisturizer in childhood atopic dermatitis. J Pediatr Nurs. 2019;47:36–43. https://doi.org/10.1016/j.pedn.2019.03.018.; Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75. https://doi.org/10.1186/s12887-016-0607-9.; Machado S. Effective use of methylprednisolone aceponate 0.1% in a 9-month-old infant with atopic eczema and sleep disturbance. J Eur Acad Dermatol Venereol. 2012;(26):14–15. https://doi.org/10.1111/j.1468-3083.2012.04712.x.; Ortonne JP. Skin atrophogenicpotencial of methylprednisolone aceponate (MPA). J Eur Acad Dermatol Venerеol. 1994;(3):13–18. https://doi.org/10.1111/j.1468-3083.1994.tb01058.x.; Романюк ФП. Взгляд педиатра на лечение атопического дерматита с применением метилпреднизолона. Медицинский совет. 2019;(17):226–234. https://doi.org/10.21518/2079-701X-2019-17-226-234.; Устинов МВ, Чаплыгин АВ. Микронизация и другие способы повышения эффективности и безопасности топических препаратов в дерматологии. Клиническая дерматология и венерология. 2019;18(4):418–427. https://doi.org/10.17116/klinderma201918041418.

الاتاحة: https://www.med-sovet.pro/jour/article/view/8718
https://doi.org/10.21518/ms2024-357

المؤلفون: Maria I. Kaleda, Irina P. Nikishina, Tamari N. Pachkoria, Anna N. Shapovalenko, М. И. Каледа, И. П. Никишина, Т. Н. Пачкория, А. Н. Шаповаленко

المساهمون: Исследование выполнено в рамках фундаментальной научной темы № 1021051302580-4.

المصدر: Rheumatology Science and Practice; Vol 62, No 4 (2024); 385–393 ; Научно-практическая ревматология; Vol 62, No 4 (2024); 385–393 ; 1995-4492 ; 1995-4484

مصطلحات موضوعية: детский возраст, belimumab, childhood, белимумаб

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3604/2387; Groot N, Shaikhani D, Teng YKO, de Leeuw K, Bijl M, Dolhain RJEM, et al. Long-term clinical outcomes in a cohort of adults with childhood-onset systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(2):290-301. doi:10.1002/art.40697; Асеева ЕА, Лила АМ, Соловьев СК, Насонов ЕЛ, Глухова СИ. Клинико-иммунологические фенотипы системной красной волчанки, выделенные на основании кластерного анализа данных 400 пациентов ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой». Современная ревматология. 2022;16(5):13-21. [Aseeva EA, Lila AM, Soloviev SK, Nasonov EL, Glukhova SI. Clinical and immunological phenotypes of systemic lupus erythematosus, identified based on cluster analysis of data from 400 patients from V.A. Nasonova Research Institute of Rheumatology. Modern Rheumatology Journal. 2022;16(5):13-21 (In Russ.)] doi:10.14412/1996-7012-2022-5-13-21; Alexander T, Hedrich CM. Systemic lupus erythematosus – Are children miniature adults? Clin Immunol. 2022;234:108907. doi:10.1016/j.clim.2021.108907; Ambrose N, Morgan TA, Galloway J, Ionnoau Y, Beresford MW, Isenberg DA; UK JSLE Study Group. Differences in disease phenotype and severity in SLE across age groups. Lupus. 2016;25(14):1542-1550. doi:10.1177/0961203316644333; Guzman M, Hui-Yuen JS. Management of pediatric systemic lupus erythematosus: Focus on belimumab. Drug Des Devel Ther. 2020;14:2503-2513. doi:10.2147/DDDT.S216193; Chen YC, Hsu CY, Tsai MC, Fu LS, Huang YC. Remission and long-term remission of pediatric-onset systemic lupus erythematosus. Front Pediatr. 2023;11:1272065. doi:10.3389/fped.2023.1272065; Smith EMD, Tharmaratnam K, Al-Abadi E, Armon K, Bailey K, Brennan M, et al. Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus. Rheumatology (Oxford). 2022;61(8):3378-3389. doi:10.1093/rheumatology/keab915; Насонов ЕЛ, Бекетова ТВ, Ананьева ЛП, Васильев ВИ, Соловьев СК, Авдеева АС. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40. [Nasonov EL, Beketova TV, Ananyeva LP, Vasilyev VI, Solovyev SK, Avdeeva AS. Prospects for anti-B-cell therapy in immuno-inflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57:1-40 (In Russ.)]. doi:10.14412/1995-4484-2019-3-40; Насонов ЕЛ, Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-383. [Nasonov EL, Popkova TV, Lila AM. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(4):367-383 (In Russ.)]. doi:10.47360/1995-4484-2021-367-383; Watson L, Beresford MW, Maynes C, Pilkington C, Marks SD, Glackin Y, et al. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus. 2015;24(1):10-17. doi:10.1177/0961203314547793; Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An update on the management of childhood-onset systemic lupus erythematosus. Paediatr Drugs. 2021;23(4):331-347. doi:10.1007/s40272-021-00457-z; Каледа МИ, Никишина ИП, Николаева ЕВ, Шаповаленко АН, Федоров ЕС, Пачкория ТН. Ритуксимаб при ревматических заболеваниях у детей: результаты ретроспективного исследования безопасности терапии. Научно-практическая ревматология. 2021;59(2):208-214. [Kaleda MI, Nikishina IP, Nikolaeva EV, Shapovalenko AN, Fedorov ES, Pachkoria TN. Rituximab for rheumatic diseases in children: Results of a retrospective study of the safety of therapy. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(2): 208-214 (In Russ.)]. doi:10.47360/1995-4484-2021-208-214; Chen F, Zheng Y, Chen X, Wen Z, Xu Y, Yang J, et al. Belimumab in childhood systemic lupus erythematosus: A review of available data. Front Immunol. 2022;13:940416. doi:10.3389/fimmu.2022.940416; Cancro MP, D’Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 2009;119(5):1066-1073. doi:10.1172/JCI38010; Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: Results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020;79(10):1340-1348. doi:10.1136/annrheumdis-2020-217101; Brunner HI, Abud-Mendoza C, Mori M, Pilkington CA, Syed R, Takei S, et al. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: An acrossstudy comparison. RMD Open. 2021;7(3):e001747. doi:10.1136/rmdopen-2021-001747; Dimelow R, Ji B, Struemper H. Pharmacokinetics of belimumab in children with systemic lupus erythematosus. Clin Pharmacol Drug Dev. 2021;10(6):622-633. doi:10.1002/cpdd.889; Hui-Yuen JS, Reddy A, Taylor J, Li X, Eichenfield AH, Bermudez LM, et al. Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol. 2015;42(12):2288-2295. doi:10.3899/jrheum.150470; Zeng P, Zeng HS, Tang XM, Zhang QY, Dang XQ. Efficacy and safety analysis of belimumab for 28 weeks in real-world Chinese children with systemic lupus erythematosus: A retrospective multicenter pilot study. Chin J Pract Pediatr. 2021;36:858-368. doi:10.19538/j.ek2021110612; Wang D, Shan C, Liu J, Zhang R, Zhu G, Gao T, et al. Efficacy and safety of belimumab for the treatment of refractory childhoodonset systemic lupus erythematosus: A single-center, real-world, retrospective study. Front Immunol. 2022;13:1067721. doi:10.3389/fimmu.2022.1067721; Wang L, Liang X, Cao Z, Wang D, Luo Y, Feng Y, et al. Evaluation of belimumab in treatment of Chinese childhood-onset systemic lupus erythematosus: A prospective analysis from a multicentre study. Rheumatology (Oxford). 2024;63(5):1437-1446. doi:10.1093/rheumatology/kead406; Kang M, Zhu J, Xu YJ, Li SN, Lai JM. [Efficacy and safety of belimumab treatment in childhood-onset systemic lupus erythematosus]. Zhonghua Yi Xue Za Zhi. 2022;102(48):3881-3885 (In Chinese). doi:10.3760/cma.j.cn112137-20220302-00438; Roberts JE, Burn C, Sadun RE, Smitherman EA, Wenderfer SE, Son MBF. Real-world use and outcomes of belimumab in childhood-onset lupus: A single-center retrospective study. Lupus. 2023;32(9):1111-1116. doi:10.1177/09612033231187752; Akbar L, Alsagheir R, Al-Mayouf SM. Efficacy of a sequential treatment by belimumab in monogenic systemic lupus erythematosus. Eur J Rheumatol. 2020;7(4):184-189. doi:10.5152/eurjrheum.2020.20087; Fontana F, Alfano G, Leonelli M, Cerami C, Ligabue G, Spinella A, et al. Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: A case report. BMC Nephrol. 2018;19(1):276. doi:10.1186/s12882-018-1066-3; Hu Y, Yuan J, Wang B, Ma L, Zha Y. Efficacy of belimumab for severe childhood-onset systemic lupus erythematosus with diffuse proliferative glomerulonephritis: A case report. Medicine (Baltimore). 2023;102(34):e34800. doi:10.1097/MD.0000000000034800; Zeng HQ, Lu XP, Yan ZB, Ye ZZ. First case presentation of refractory pediatric bullous lupus erythematosus (BSLE) treatment with belimumab. Eur Rev Med Pharmacol Sci. 2022;26(21): 7980-7985. doi:10.26355/eurrev_202211_30151; Lou L, Guo H, Shao M. Systemic lupus erythematosus complicated with Fanconi syndrome: A case report and literature review. Front Pediatr. 2024;11:1230366. doi:10.3389/fped.2023.1230366; Каледа МИ, Никишина ИП, Фирса АВ. Применение белимумаба у пациентки с системной красной волчанкой с ювенильным дебютом и стероидным диабетом: клинический случай. Вопросы современной педиатрии. 2023;22(6):546-553. [Kaleda MI, Nikishina IP, Firsa AV. Belimumab in a patient with systemic lupus erythematosus with juvenile onset and steroid-induced diabetes: Clinical case. Current Pediatrics. 2023;22(6):546-553 (In Russ.)]. doi:10.15690/vsp.v22i6.2649; Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi:10.1002/art.34473; Lattanzi B, Consolaro A, Solari N, Ruperto N, Martini A, Ravelli A. Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician’s Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S112-S117. doi:10.1002/acr.20623; Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. doi:10.1136/ard-2023-224762; Smith EMD, Aggarwal A, Ainsworth J, Al-Abadi E, Avcin T, Bortey L, et al.; cSLE T2T International Task Force. Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task force. Ann Rheum Dis. 2023;82(6):788-798. doi:10.1136/ard-2022-223328; Williams CEC, Lamond M, Marro J, Chetwynd AJ, Oni L. A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP). Clin Rheumatol. 2023;42(12):3189-3200. doi:10.1007/s10067-023-06781-8; Vivarelli M, Colucci M, Gargiulo A, Bettini C, Lo Russo A, Emma F. Belimumab for the treatment of children with frequently relapsing nephrotic syndrome: The BELNEPH study. Pediatr Nephrol. 2022;37(2):377-383. doi:10.1007/s00467-021-05175-9; Van Vollenhoven RF, Navarra SV, Levy RA, Thomas M, Heath A, Lustine T, et al. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: A phase III study extension. Rheumatology (Oxford). 2020;59(2):281-291. doi:10.1093/rheumatology/kez279; https://rsp.mediar-press.net/rsp/article/view/3604

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/3604
https://doi.org/10.47360/1995-4484-2024-385-393

المؤلفون: Olga Ya. Smirnova, Nato D. Vashakmadze, Maria S. Karaseva, Natalia V. Zhurkova, Anna Yu. Rachkova, Leyla S. Namazova-Baranova, О. Я. Смирнова, Н. Д. Вашакмадзе, М. С. Карасева, Н. В. Журкова, А. Ю. Рачкова, Л. С. Намазова-Баранова

المساهمون: Not specified., Отсутствует.

المصدر: Current Pediatrics; Том 23, № 1 (2024); 6-12 ; Вопросы современной педиатрии; Том 23, № 1 (2024); 6-12 ; 1682-5535 ; 1682-5527

مصطلحات موضوعية: агалсидаза-бета, GLA gene, α-galactosidase А, lyso-Gb3, childhood, neuropathic pain, acroparesthesia, angiokeratoma, hyphidrosis, vortex keratopathy, agalsidase alpha, agalsidase beta, ген GLA, α-галактозидаза А, детский возраст, нейропатическая боль, акропарестезии, ангиокератомы, гипогидроз, вихревидная кератопатия, агалсидаза-альфа

وصف الملف: application/pdf

Relation: https://vsp.spr-journal.ru/jour/article/view/3394/1356; Germain DP. Fabry disease. Orphanet J Rare Dis. 2010; 5: 30. doi: https://doi.org/10.1186/1750-1172-5-30; Hopkin RJ, Bissler J, Banikazemi M, et al. Characterization of Fabry Disease in 352 Pediatric Patients in the Fabry Registry. Pediatr Res. 2008;64(5):550–555. doi: https://doi.org/10.1203/PDR.0b013e318183f132; Schiffmann R, Hughes DA, Linthorst GE, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2017;91(2): 284–293. doi: https://doi.org/10.1016/j.kint.2016.10.004; Каровайкина Е.А., Моисеев А.С., Буланов Н.М. и др. Скрининг, диагностика и лечение болезни Фабри // Клиническая фармакология и терапия. — 2019. — Т. 28. — № 3. — С. 68–74. — doi: https://doi.org/1010.32756/0869-5490-2019-3-68-74; Ouyang Y, Chen B, Pan X, et al. Clinical significance of plasma globotriaosylsphingosine levels in Chinese patients with Fabry disease. Exp Ther Med. 2018;15(4):3733-42. doi: https://doi.org/10.3892/etm.2018.5889.; Nowak A, Mechtler TP, Desnick RJ, Kasper DC. Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Mol Genet Metab. 2017;120(1-2):57–61. doi: https://doi.org/10.1016/j.ymgme.2016.10.006; Maruyama H, Miyata K, Mikame M, et al. Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis. Genet Med. 2019;21(1):44–52. doi: https://doi.org/10.1038/gim.2018.31; Maron MS, Xin W, Sims KB, et al. Identification of Fabry disease in a tertiary referral cohort of patients with hypertrophic cardiomyopathy. Am J Med. 2018;131(2):200.e1–200.e8. doi: https://doi.org/10.1016/j.amjmed.2017.09.010; Newman DB, Miranda WR, Matern D, et al. Cost efficacy of α-galactosidase A enzyme screening for Fabry disease. Mayo Clin Proc. 2019;94(1):84–88. doi: https://doi.org/10.1016/j.mayocp.2018.08.009; Wozniak MA, Kittner SJ, Tuhrim S, et al. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke. 2010;41(1): 78–81. doi: https://doi.org/10.1161/STROKEAHA.109.558320; Rolfs A, Buttcher T, Zschiesche M, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005;366(9499):1794–1796. doi: https://doi.org/10.1016/S0140-6736(05)67635-0; Reisin RC, Mazziotti J, Cejas LL, et al. Prevalence of Fabry disease in young patients with stroke in Argentina. J Stroke Cerebrovasc Dis. 2018;27(3):575–582. doi: https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.09.045; Song X, Xue S, Zhao J, Wu J. Screening for Fabry’s disease in young patients with ischemic stroke in a Chinese population. Int J Neurosci. 2017;127(4):350–355. doi: https://doi.org/10.3109/00207454.2016.1166107; Laney DA, Fernh PM. Diagnosis of Fabry disease via analysis of family history. J Genet Counsel. 2008;17(1):79–83. doi: https://doi.org/10.1007/s10897-007-9128-x; Болезнь Фабри: клинические рекомендации / Ассоциация медицинских генетиков; Союз педиатров России. — 2019. — 53 c.; Moore DF, Goldin E, Gelderman MP, et al. Apoptotic abnormalities in differential gene expression in peripheral blood mononuclear cells from children with Fabry disease. Acta Paediatr. 2008;97(457): 48–52. doi: https://doi.org/10.1111/j.1651-2227.2008.00654.x; De Francesco PN, Mucci JM, Ceci R, et al. Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide. Mol Genet Metab. 2013;109(1):93–99. doi: https://doi.org/10.1016/j.ymgme.2013.02.003; Fujinaga S, Murakami H, Kubota M, et al. Is there a pathogenic association between Fabry’s disease and IgA nephropathy? Clin Nephrol Case Stud. 2013;1:14–17. doi: https://doi.org/10.5414/CNCS107994; Martinez P, Aggio M, Rozenfeld P. High incidence of autoantibodies in Fabry disease patients. J Inherit Metab Dis. 2007;30(3): 365–369. doi: https://doi.org/10.1007/s10545-007-0513-2; Lyon MF. Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature. 1961;190:372–373. doi: https://doi.org/10.1038/190372a0; Фирсов К.В., Котов А.С. Неврологические проявления болезни Фабри у детей и подростков // Русский журнал детской неврологии. — 2017. — Т. 12. — № 3. — С. 51–57. — doi: https://doi.org/10.17650/2073-8803-2017-12-3-51-57; Yoo HW. Fabry disease: current treatment and future perspective. J Genet Med. 2023;20(1):6-14. doi: https://doi.org/10.5734/JGM.2023.20.1.6; McCafferty EH, Scott LJ. Migalastat: a review in Fabry disease. Drugs. 2019;79(5):543–554. doi: https://doi.org/10.1007/s40265-019-01090-4; Войтенков В.Б., Екушева Е.В. Болевой синдром при болезни Фабри: семиотика, диагностика и лечение // РМЖ. — 2019. — № 9. — С. 50–54.; Моисеев С.В., Исмаилова Д.С., Моисеев А.С. и др. Вихревидная кератопатия (cornea verticillata) при болезни Фабри // Терапевтический архив. — 2018. — Т. 90. — № 12. — С. 17–22. — doi: https://doi.org/10.26442/00403660.2018.12.000003; Gambini G, Scartozzi L, Giannuzzi F, et al. Ophthalmic anifestations in Fabry Disease: Updated Review. J Pers Med. 2023;13(6):904. doi: https://doi.org/10.3390/jpm13060904; Cordeiro CA, Oréfice F, Lasmar EP, et al. Cornea verticillata — a clinical marker of Fabry disease: case report. Arq Bras Oftalmol. 2007;70(4):701–705. doi: https://doi.org/10.1590/s0004-27492007000400024; Tondel C, Bostad L, Hirth A, Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis. 2008;51(5):767–776. doi: https://doi.org/10.1053/j.ajkd.2007.12.032; Моисеев С.В., Мершина Е.А., Синицын В.Е. и др. Магнитнорезонансная томография в диагностике поражения сердца при болезни Фабри // Клиническая фармакология и терапия. — 2017. — Т. 26. — № 3. — С. 13–20.; Cortes-Saladelafont E, Fernandez-Martin J, Ortolano S. Fabry Disease and Central Nervous System Involvement: From Big to Small, from Brain to Synapse. Int J Mol Sci. 2023;24(6):5246. doi: https://doi.org/10.3390/ijms24065246; Моисеев А.С., Тао Е.А., Буланов Н.М. и др. Поражение центральной нервной системы при болезни Фабри // Клиническая фармакология и терапия. — 2022. — Т. 31. — № 1. — С. 32–38. — doi: https://doi.org/10.32756/0869-5490-2022-1-32-38; Моисеев С.В., Новиков П.И., Буланов Н.М. и др. Болезнь Фабри в практике ревматолога // Клиническая фармакология и терапия. — 2018. — Т. 27. — № 1. — С. 39–45; Manna R, Cauda R, Feriozzi S, et al. Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin. Intern Emerg Med. 2017;12(7):1059–1067. doi: https://doi.org/10.1007/s11739-017-1704-y; Sakuraba H, Togawa T, Tsukimura T, et al. Plasma lyso-Gb3: a biomarker for monitoring Fabry patients during enzyme replacement therapy. Clin Exp Nephrol. 2018;22(4):843–849. doi: https://doi.org/10.1007/s10157-017-1525-3; Polo G, Burlina A, Ranieri E, et al. Plasma and dried blood spot lysosphingolipids for the diagnosis of different sphingolipidoses: a comparative study. Clin Chem Lab Med. 2019;57(12): 1863–1874. doi: https://doi.org/10.1515/cclm-2018-1301; Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416–427. doi: https://doi.org/10.1016/j.ymgme.2018.02.014; Biegstraaten M, Arngrнmsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10:36. doi: https://doi.org/10.1186/s13023-015-0253-6; Инструкция по медицинскому применению препарата Реплагал. № ЛСР-00551/09.; Инструкция по медицинскому применению препарата Фабразим. № ЛСР-003334/09.; Hwang S, Lee BH, Kim WS, et al. A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease. Medicine (Baltimore). 2022;101(37):e30345. doi: https://doi.org/10.1097/MD.0000000000030345; Germain DP, Elliott PM, Falissard B, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts. Mol Genet Metab Rep. 2019;19:100454. doi: https://doi.org/10.2174/1381612826666200317142412; Germain DP, Arad M, Burlina A, et al. The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease — A systematic literature review by a European panel of experts. Mol Genet Metab. 2019;126(3):224–235. doi: https://doi.org/10.1016/j.ymgme.2018.09.007; Hopkin RJ, Cabrera G, Charrow J, et al. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: data from the Fabry Registry. Mol Genet Metab. 2016;119(1-2): 151–159. doi: https://doi.org/10.1016/j.ymgme.2016.06.007; Riccio E, Pisani A. New insights in efficacy of different enzyme replacement therapy dosages in Fabry disease: switch studies data following agalsidase beta shortage. Clin Genet. 2023;103(3): 371–376. doi: https://doi.org/10.1111/cge.14266; Lenders M, Brand E. Fabry disease: the current treatment landscape. Drugs. 2021;81(6):635–645. doi: https://doi.org/10.1007/s40265-021-01486-1; Germain DP, Altarescu G, Barriales-Villa R, et al. An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease. Mol Genet Metab. 2022;137 (1-2):49–61. doi: https://doi.org/10.1016/j.ymgme.2022.07.010; Politei JM, Bouhassira D, Germain DP, et al. Pain in Fabry disease: practical recommendations for diagnosis and treatment. CNS Neurosci Ther. 2016;22(7):568–576. doi: https://doi.org/10.1111/cns.12542; Mehta A, West ML. Therapeutic goals in the treatment of Fabry disease. Genet Med. 2010;12(11):713–720. doi: https://doi.org/10.1097/GIM.0b013e3181f6e676; Laney DA, Bennett RL, Clarke V, et al. Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors. J Genet Couns. 2013;22(5):555–564. doi: https://doi.org/10.1007/s10897-013-9613-3; https://vsp.spr-journal.ru/jour/article/view/3394

الاتاحة: https://vsp.spr-journal.ru/jour/article/view/3394
https://doi.org/10.15690/vsp.v23i1.2652

المؤلفون: Rostovtseva, Marina E., Ростовцева, Марина Е.

المصدر: Russian Psychological Journal; Vol. 21 No. 1 (2024); 87-107 ; Российский психологический журнал; Том 21 № 1 (2024); 87-107 ; 2411-5789 ; 1812-1853 ; 10.21702/w59f0g27

مصطلحات موضوعية: понимание смерти, концепция смерти, детский возраст, психология развития, танатопсихология, страх смерти, тревога, танатическая тревога, understanding death, concept of death, childhood, developmental psychology, thanatopsychology, fear of death, anxiety, death anxiety

وصف الملف: application/pdf

Relation: https://rpj.ru.com/index.php/rpj/article/view/1615/1821; https://rpj.ru.com/index.php/rpj/article/view/1615/1822; https://rpj.ru.com/index.php/rpj/article/view/1615

الاتاحة: https://rpj.ru.com/index.php/rpj/article/view/1615
https://doi.org/10.21702/rpj.2024.1.5

المؤلفون: M. I. Kaleda, I. P. Nikishina, М. И. Каледа, И. П. Никишина

المساهمون: The article was prepared within the framework of the basic scientific topic №1021051302580-4., Статья подготовлена в рамках фундаментальной научной темы №1021051302580-4.

المصدر: Modern Rheumatology Journal; Том 18, № 2 (2024); 95-102 ; Современная ревматология; Том 18, № 2 (2024); 95-102 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: детский возраст, monogenic lupus, childhood, моногеннная волчанка

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1568/1464; Levy DM, Kamphuis S. Systemic Lupus Erythematosus in Children and Adolescents. Pediatr Clin North Am. 2012 Apr;59(2):345-64. doi:10.1016/j.pcl.2012.03.007.; Groot N, Shaikhani D, Teng YKO, et al. Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 Feb;71(2):290-301. doi:10.1002/art.40697.; Асеева ЕА, Лила АМ, Соловьев СК и др.Клинико-иммунологические фенотипы системной красной волчанки, выделенные на основании кластерного анализа данных 400 пациентов ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой». Современная ревматология. 2022;16(5):13-21.; Smith EMD, Lythgoe H, Midgley A, et al. Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. Clin Immunol. 2019 Dec:209:108274. doi:10.1016/j.clim.2019.108274. Epub 2019 Oct 31.; Huang JL, Yao TC, See LC. Prevalence ofpediatric systemic lupus erythematosus and juvenile chronic arthritis in a Chinese population: a nation-wide prospective populationbased study in Taiwan. Clin Exp Rheumatol. 2004 Nov-Dec;22(6):776-80.; Series OR. List of rare diseases and synonyms listed in alphabetical order: orphanet, 2021. http://www.orpha.net/orphacom/cahiers/docs/GB/List_of_rare_diseases_in_alphabetical_order.pdf; Alexander T, Hedrich CM. Systemic lupuserythematosus – Are children miniature adults? Clin Immunol. 2022 Jan:234:108907. doi:10.1016/j.clim.2021.108907. Epub 2021 Dec 8.; Hedrich CM, Smith EMD, Beresford MW. Juvenile-onset systemic lupus erythematosus (jSLE) – Pathophysiological concepts and treatment options. Best Pract Res Clin Rheumatol. 2017 Aug;31(4):488-504. doi:10.1016/j.berh.2018.02.001. Epub 2018 Mar 1.; Kwon YC, Chun S, Kim K, Mak A. Updateon the Genetics of Systemic Lupus Erythematosus: Genome-Wide Association Studies and Beyond. Cells. 2019 Sep 30;8(10):1180. doi:10.3390/cells8101180.; Kuo CF, Grainge MJ, Valdes AM, et al. Familial Aggregation of Systemic Lupus Erythematosus and Coaggregation of Autoimmune Diseases in Affected Families. JAMA Intern Med. 2015 Sep;175(9):1518-26. doi:10.1001/jamainternmed.2015.3528.; Sestan M, Kifer N, Arsov T, et al The Roleof Genetic Risk Factors in Pathogenesis of Childhood-Onset Systemic Lupus Erythematosus. Curr Issues Mol Biol. 2023 Jul 17;45(7): 5981-6002. doi:10.3390/cimb45070378.; Caielli S, Wan Z, Pascual V. Systemic Lupus Erythematosus Pathogenesis: Interferon and Beyond. Annu Rev Immunol. 2023 Apr 26: 41:533-560. doi:10.1146/annurev-immunol101921-042422. Epub 2023 Feb 28.; Ardoin SP, Daly RP, Merzoug L, et al;Childhood Arthritis and Rheumatology Research Alliance and Lupus Foundation of America. Research priorities in childhood-onset lupus: results of a multidisciplinary prioritization exercise. Pediatr Rheumatol Online J. 2019 Jul 1;17(1):32. doi:10.1186/s12969-0190327-4.; Yu H, Nagafuchi Y, Fujio K. Clinical andImmunological Biomarkers for Systemic Lupus Erythematosus. Biomolecules. 2021 Jun 22;11(7):928. doi:10.3390/biom11070928.; Li H, Wang T, Li B, et al. Bioinformaticanalysis of immune-related transcriptome affected by IFIT1 gene in childhood systemic lupus erythematosus. Transl Pediatr. 2023 Aug 30;12(8):1517-1526. doi:10.21037/tp-23-365. Epub 2023 Aug 21.; Ambrose N, Morgan TA, Galloway J, et al;UK JSLE Study Group. Differences in disease phenotype and severity in SLE across age groups. Lupus. 2016 Dec;25(14):1542-1550. doi:10.1177/0961203316644333; Oni L, Wright RD, Marks S, et al. Kidney outcomes for children with lupus nephritis. Pediatr Nephrol. 2021 Jun;36(6):1377-1385. doi:10.1007/s00467-020-04686-1; Hsu TC, Yang YH, Wang LC, et al. Risk factors for subsequent lupus nephritis in patients with juvenile-onset systemic lupus erythematosus: a retrospective cohort study. Pediatr Rheumatol Online J. 2023 Mar 24;21(1):28. doi:10.1186/s12969-023-00806-x; Chan EY, Lai FF, Ma AL, Chan TM. Managing Lupus Nephritis in Children and Adolescents. Paediatr Drugs. 2023 Dec 20. doi:10.1007/s40272-023-00609-3. Online ahead of print.; Appenzeller S, Pereira DR, Julio PR, et al. Neuropsychiatric manifestations in childhoodonset systemic lupus erythematosus. Lancet Child Adolesc Health. 2022 Aug;6(8):571-581. doi:10.1016/S2352-4642(22)00157-2.; Natoli V, Charras A, Hahn G, Hedrich CM. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus (jSLE). Mol Cell Pediatr. 2023 Aug 9;10(1):5. doi:10.1186/s40348-023-00161-7.; Каледа МИ, Никишина ИП, Глухова СИ, Степаненко НЮ. Нейропсихические нарушения при ювенильном дебюте системной красной волчанки: результаты ретроспективного исследования. Научно-практическая ревматология. 2020;58(2):171-177.; Hiraki LT, Benseler SM, Tyrrell PN, et al.Ethnic differences in pediatric systemic lupus erythematosus. J Rheumatol. 2009 Nov;36(11): 2539-46. doi:10.3899/jrheum.081141. Epub 2009 Oct 15.; Watson L, Leone V, Pilkington C, et al;UK Juvenile-Onset Systemic Lupus Erythematosus Study Group. Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort. Arthritis Rheum. 2012 Jul;64(7):2356-65. doi:10.1002/art.34410.; Massias JS, Smith EMD, Al-Abadi E, et al. Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. Lupus. 2020 Apr;29(5):474481. doi:10.1177/0961203320909156. Epub 2020 Mar 31.; Massias JS, Smith EM, Al-Abadi E, et al.Clinical and laboratory phenotypes in juvenileonset Systemic Lupus Erythematosus across ethnicities in the UK. Lupus. 2021 Apr; 30(4):597-607. doi:10.1177/0961203320984251. Epub 2021 Jan 7.; Alperin JM, Ortiz-Fernandez L, Sawalha AH.Monogenic Lupus: A Developing Paradigm of Disease. Front Immunol. 2018 Oct 30:9:2496. doi:10.3389/fimmu.2018.02496.eCollection 2018.; Harley ITW, Sawalha AH. Systemic lupuserythematosus as a genetic disease. Clin Immunol. 2022 Mar;236:108953. doi:10.1016/j.clim.2022.108953; Misztal MC, Liao F, Couse M, et al. Genome-Wide Sequencing Identified Rare Genetic Variants for Childhood-Onset Monogenic Lupus. J Rheumatol. 2023 May;50(5):671-675. doi:10.3899/jrheum.220513. Epub 2022 Nov 15.; Demirkaya E, Sahin S, Romano M, et al. New Horizons in the Genetic Etiology of Systemic Lupus Erythematosus and Lupus-Like Disease: Monogenic Lupus and Beyond. J Clin Med. 2020 Mar 5;9(3):712. doi:10.3390/jcm9030712.; Al-Mayouf SM, Alkhars F, AlSaleem A. Phenotype and disease course differences in monogenic and sporadic childhood lupus. Lupus. 2023 Nov;32(13):1548-1554. doi:10.1177/09612033231211065. Epub 2023 Oct 25.; Belot A, Rice GI, Omarjee SO, et al; FREX Consortium; GENIAL Investigators; UK JSLE Study Group. Contribution of rare and predicted pathogenic gene variants to childhood-onset lupus: a large, genetic panel analysis of British and French cohorts. Lancet Rheumatol. 2020 Feb;2(2):e99-e109. doi:10.1016/S2665-9913(19)30142-0. Epub 2020 Jan 13.9; Kim H, Sanchez GA, Goldbach-Mansky R. Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus. J Mol Med (Berl). 2016 Oct;94(10):1111-1127. doi:10.1007/s00109016-1465-5. Epub 2016 Sep 27.; Nigrovic PA, Lee PY, Hoffman HM. Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach. J Allergy Clin Immunol. 2020 Nov;146(5): 925-937. doi:10.1016/j.jaci.2020.08.017.; Sandling JK, Pucholt P, Hultin Rosenberg L, et al. Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. Ann Rheum Dis. 2021 Jan;80(1):109-117. doi:10.1136/annrheumdis-2020-218636; Al-Mayouf SM, Alreefi HA, Alsinan TA, et al. Lupus manifestations in children with primary immunodeficiency diseases: Comprehensive phenotypic and genetic features and outcome. Mod Rheumatol. 2021 Nov;31(6): 1171-1178. doi:10.1080/14397595.2021.1886627. Epub 2021 Feb 22.; Sawada T, Fujimori D, Yamamoto Y. Systemic lupus erythematosus and immunodeficiency. Immunol Med. 2019 Mar;42(1):1-9. doi:10.1080/25785826.2019.1628466. Epub 2019 Jun 17.; Hoyt KJ, Chatila TA, Notarangelo LD, et al. The immunologic features of patients with early-onset and polyautoimmunity. Clin Immunol. 2020 Feb:211:108326. doi:10.1016/j.clim.2019.108326. Epub 2019 Dec 12.; Sharifinejad N, Azizi G, Chavoshzadeh Z,et al. Autoimmunity in monogenic combined immune deficiencies with associated or syndromic features. Front Immunol. 2022 Dec 5:13: 1023127. doi:10.3389/fimmu.2022.1023127.eCollection 2022.; Li YR, Li J, Zhao SD, et al. Meta-analysisof shared genetic architecture across ten pediatric autoimmune diseases. Nat Med. 2015 Sep;21(9):1018-27. doi:10.1038/nm.3933. Epub 2015 Aug 24.; Molano-Gonzalez N, Rojas M, Monsalve DM, et al. Cluster analysis of autoimmune rheumatic diseases based on autoantibodies. New insights for polyautoimmunity. J Autoimmun. 2019 Mar:98:24-32. doi:10.1016/j.jaut.2018.11.002. Epub 2018 Nov 17.; Malagуn C, Gomez MDP, Mosquera C, et al. Juvenile polyautoimmunity in a rheumatology setting. Autoimmun Rev. 2019 Apr; 18(4):369-381. doi:10.1016/j.autrev.2018.11.006. Epub 2019 Feb 14.; Setoue DN, Pitta AC, Fiorot FJ, et al; Brazilian Childhood-onset Systemic Lupus Erythematosus Group. Symptomatic polyautoimmunity at diagnosis of 1463 childhoodonset lupus: A Brazilian multicenter study. Autoimmun Rev. 2018 Aug;17(8):836-839. doi:10.1016/j.autrev.2018.03.009. Epub 2018 Jun 7.; Lythgoe H, Lj M, Hedrich CM, Aringer M.Classification of systemic lupus erythematosus in children and adults. Clin Immunol. 2022 Jan:234:108898. doi:10.1016/j.clim.2021.108898. Epub 2021 Nov 29.; Batu ED, Akca UK, Kisaarslan AP, et al.The Performances of the ACR 1997, SLICC 2012, and EULAR/ACR 2019 Classification Criteria in Pediatric Systemic Lupus Erythematosus. J Rheumatol. 2021 Jun;48(6): 907-914. doi:10.3899/jrheum.200871. Epub 2020 Nov 15.; Chang LS, Huang PY, Kuo HC, et al. Diagnostic accuracy of the American College of Rheumatology-1997, the Systemic Lupus International Collaborating Clinics-2012, and the European League Against Rheumatism2019 criteria for juvenile systemic lupus erythematosus: A systematic review and network meta-analysis. Autoimmun Rev. 2022 Sep; 21(9):103144. doi:10.1016/j.autrev.2022.103144. Epub 2022 Jul 13.; Ohara A, Iwata N, Sugiura S, et al. Evaluation of the European League Against Rheumatism/American College of Rheumatology-2019 classification criteria in patients with childhood-onset systemic lupus erythematosus: a single-center retrospective study. Clin Rheumatol. 2022 Aug;41(8):2483-2489. doi:10.1007/s10067-022-06138-7. Epub 2022 Apr 4.; Al-Mayouf SM, Akbar L, Abdwani R, et al. Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematous in monogenic lupus. Clin Rheumatol. 2022 Sep;41(9):2721-2727. doi:10.1007/s10067-022-06209-9. Epub 2022 May 19.; Brunner HI, Huggins J, Klein-Gitelman MS. Pediatric SLE-towards a comprehensive management plan. Nat Rev Rheumatol. 2011 Apr;7(4):225-33. doi:10.1038/nrrheum.2011.15. Epub 2011 Mar 8.; Aragon E, Resontoc LP, Chan YH, et al. Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis. Lupus. 2016 Apr;25(4):399-406. doi:10.1177/0961203315 615220. Epub 2015 Nov 3.; Smith EMD, Tharmaratnam K, Al-Abadi E,et al. Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus. Rheumatology (Oxford). 2022 Aug 3;61(8):33783389. doi:10.1093/rheumatology/keab915.; Chen YC, Hsu CY, Tsai MC, et al. Remission and long-term remission of pediatric-onset systemic lupus erythematosus. Front Pediatr. 2023 Oct 27:11:1272065. doi:10.3389/fped.2023.1272065. eCollection 2023.; Falcini F, Nacci F. Systemic lupus erythematosus in the young: the importance of a transition clinic. Lupus. 2007;16(8):613-7. doi:10.1177/0961203307078973.; Groot N, de Graeff N, Avcin T, et al.European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis. 2017 Nov;76(11): 1788-1796. doi:10.1136/annrheumdis-2016210960. Epub 2017 Jun 19.; Gutierrez-Suarez R, Ruperto N, Gastaldi R, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 2006 Sep; 54(9):2989-96. doi:10.1002/art.22048.; Ozturk K, Caglayan S, Tanatar A, et al;PeRA-Research Group. Low disease activity state in juvenile-onset systemic lupus erythematosus. Lupus. 2021 Nov;30(13):2144-2150. doi:10.1177/09612033211054399. Epub 2021 Nov 1.; Na Nakorn K, Piyaphanee N, Sukharomana M, et al. Outcomes of achieving lupus low disease activity state and damage accrual in childhood-onset systemic lupus erythematosus. Clin Rheumatol. 2023 Jun;42(6):16551664. doi:10.1007/s10067-023-06533-8. Epub 2023 Feb 13.; Bao S, Huang H, Jin Y, et al. Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus. Lupus Sci Med. 2023 Apr;10(1): e000834. doi:10.1136/lupus-2022-000834.; Groot N, de Graeff N, Marks SD, et al. European evidence-based recommendations for the diagnosis and treatment of childhoodonset lupus nephritis: the SHARE initiative. Ann Rheum Dis. 2017 Dec;76(12):1965-1973. doi:10.1136/annrheumdis-2017-211898. Epub 2017 Sep 6.; Groot N, de Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Ann Rheum Dis. 2017 Oct;76(10):16371641. doi:10.1136/annrheumdis-2016211001. Epub 2017 May 4.; Алексеева ЕИ, Дворяковская ТМ, Никишина ИП и др. Системная красная волчанка: клинические рекомендации. Часть 2. Вопросы современной педиатрии. 2018;17(2):110-25.; Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019 Jun; 78(6):736-745. doi:10.1136/annrheumdis2019-215089. Epub 2019 Mar 29.; Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus. Paediatr Drugs. 2021 Jul; 23(4):331-347. doi:10.1007/s40272-02100457-z. Epub 2021 Jul 10.; Hammam N, Evans M, Bell CF, et al. Evaluating the Use of Glucocorticoids Among Belimumab-Treated Patients With Systemic Lupus Erythematosus in Real-World Settings Using the Rheumatology Informatics System for Effectiveness Registry. ACR Open Rheumatol. 2022 Oct;4(10):883-889. doi:10.1002/acr2.11482. Epub 2022 Jul 24.; Chen F, Zheng Y, Chen X, et al. Belimumab in childhood systemic lupus erythematosus: A review of available data. Front Immunol. 2022 Jul 27:13:940416. doi:10.3389/fimmu.2022.940416. eCollection 2022.; Lim LSH, Pullenayegum E, Lim L, et al.From childhood to adulthood: the trajectory of damage in patients with juvenile-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017 Nov;69(11):1627-1635. doi:10.1002/acr.23199. Epub 2017 Sep 26.; Smith E, Al-Abadi E, Armon K, et al.Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis. Lupus. 2019 Apr;28(5):613-620. doi:10.1177/0961203319836712. Epub 2019 Mar 14.; Brunner HI, Vadhariya A, Dickson C, et al.Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA. Lupus Sci Med. 2023 Jul; 10(2):e000817. doi:10.1136/lupus-2022000817.; Mao Y, Yin L, Huang H, et al. Addition ofcyclosporine/tacrolimus for pediatric relapsed lupus nephritis during mycophenolate mofetil maintenance therapy. J Int Med Res. 2019 Jan; 47(1):105-113. doi:10.1177/0300060518796751. Epub 2018 Sep 12.; Jansson AF, Sengler C, KuemmerleDeschner J, et al. B cell depletion for autoimmune diseases in paediatric patients. Clin Rheumatol. 2011 Jan;30(1):87-97. doi:10.1007/s10067-010-1630-0. Epub 2010 Dec 1.; Merino-Vico A, Frazzei G, van Hamburg JP,Tas SW. Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches. Eur J Immunol. 2023 Jan;53(1):e2149675. doi:10.1002/eji.202149675. Epub 2022 Nov 16.; Насонов ЕЛ, Бекетова ТВ, Ананьева ЛПи др. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40. [; Mahmoud I, Jellouli M, Boukhris I, et al.Efficacy and Safety of Rituximab in the Management of Pediatric Systemic Lupus Erythematosus: A Systematic Review. J Pediatr. 2017 Aug:187:213-219.e2. doi:10.1016/j.jpeds.2017.05.002.; Sawhney S, Agarwal M. Rituximab use inpediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort. Lupus. 2021 Oct;30(11):1829-1836. doi:10.1177/09612033211034567. Epub 2021 Jul 27.; Каледа МИ, Никишина ИП, Николаева ЕВ и др. Ритуксимаб при ревматических заболеваниях у детей: результаты ретроспективного исследования безопасности терапии. Научно-практическая ревматология. 2021;59(2):208-214; Cinar OK, Marlais M, Al Obaidi M, et al. Ofatumumab use in juvenile systemic lupus erythematosus: A single centre experience. Lupus. 2021 Mar;30(3):527-530. doi:10.1177/0961203320981137; Lei L, Muhammad S, Al-Obaidi M, et al. Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase Cδ. Pediatr Rheumatol Online J. 2018 Sep 26;16(1): 61. doi:10.1186/s12969-018-0278-1.; Насонов ЕЛ, Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021; 59(4):367-383.; Guzman M, Hui-Yuen JS. Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab. Drug Des Devel Ther. 2020 Jun 25:14:2503-2513. doi:10.2147/DDDT.S216193.eCollection 2020.; Brunner HI, Abud-Mendoza C, Viola DO, et al; Paediatric Rheumatology International Trials Organisation (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020 Oct;79(10):1340-1348. doi:10.1136/annrheumdis-2020-217101. Epub 2020 Jul 22.; Hui-Yuen JS, Reddy A, Taylor J, et al. Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices. J Rheumatol. 2014 Apr; 41(4):759-67. doi:10.3899/jrheum.130690. Epub 2014 Mar 15.; Ramaswamy M, Tummala R, Streicher K,et al. The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases. Int J Mol Sci. 2021 Oct 19;22(20):11286. doi:10.3390/ijms222011286.; Shaw KS, Rajeh A, Le T, et al. Anifrolumab for Adolescent Discoid Lupus Erythematosus. JAMA Netw Open. 2023 Oct 2;6(10): e2338200. doi:10.1001/jamanetworkopen.2023.38200.; Pin A, Tesser A, Pastore S, Moressa V, et al. Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK Inhibitors. Int J Mol Sci. 2020 Oct 20;21(20): 7767. doi:10.3390/ijms21207767.; Chuprin J, McCormack L, Richmond JM,Rashighi M. Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: an update. Expert Rev Clin Immunol. 2022 Mar;18(3):263-272. doi:10.1080/1744666X.2022.2047022. Epub 2022 Mar 4.; Rossano M, Conti EA, Bocca P, et al. Novel heterozygous TREX1 mutation in a juvenile systemic lupus erythematosus patient with severe cutaneous involvement treated successfully with Jak-inhibitors: a case report. Front Immunol. 2023 Dec 6:14:1288675. doi:10.3389/fimmu.2023.1288675.eCollection 2023.; https://mrj.ima-press.net/mrj/article/view/1568

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1568
https://doi.org/10.14412/1996-7012-2024-2-95-102

المؤلفون: M. I. Kaleda, I. P. Nikishina, A. N. Latypova, N. N. Yudkina, Zh. G. Verizhnikova, A. N. Shapovalenko, T. N. Pachkoria, М. И. Каледа, И. П. Никишина, А. Н. Латыпова, Н. Н. Юдкина, Ж. Г. Верижникова, А. Н. Шаповаленко, Т. Н. Пачкория

المساهمون: Исследование выполнено в рамках фундаментальной научной темы №1021051302580-4.

المصدر: Modern Rheumatology Journal; Том 18, № 1 (2024); 62-69 ; Современная ревматология; Том 18, № 1 (2024); 62-69 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: детский возраст, antibodies against ribonucleoprotein, childhood, антитела к рибонуклеопротеину

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1533/1439; https://mrj.ima-press.net/mrj/article/view/1533/1449; Ferrara CA, La Rocca G, Ielo G, et al. Towards Early Diagnosis of Mixed Connective Tissue Disease: Updated Perspectives. Immunotargets Ther. 2023 Jul 26:12:79-89. doi:10.2147/ITT.S390023. eCollection 2023.; Smolen JS, Steiner G. Mixed connective tissue disease: to be or not to be? Arthritis Rheum. 1998 May;41(5):768-77. doi:10.1002/1529-0131(199805)41:5 3.0.CO;2-Z.; Aringer M, Steiner G, Smolen JS. Does mixed connective tissue disease exist? Yes. Rheum Dis Clin North Am. 2005 Aug;31(3): 411-20, v. doi:10.1016/j.rdc.2005.04.007.; Batu ED, Günalp A, Sahin S, et al. Pediatric mixed connective tissue disease versus other overlap syndromes: a retrospective multicenter cohort study. Rheumatol Int. 2023 Aug; 43(8):1485-1495. doi:10.1007/s00296-023-05300-x. Epub 2023 Mar 12.; Gunnarsson R, Molberg O, Gilboe IM, Gran JT; PAHNOR1 Study Group. The prevalence and incidence of mixed connective tissue disease: a national multicentre survey of Norwegian patients. Ann Rheum Dis. 2011 Jun;70(6):1047-51. doi:10.1136/ard.2010.143792. Epub 2011 Mar 11.; Swart JF, Wulffraat NM. Diagnostic workup for mixed connective tissue disease in childhood. Isr Med Assoc J. 2008 Aug-Sep; 10(8-9):650-2.; Alves MR, Isenberg DA. "Mixed connective tissue disease": a condition in search of an identity. Clin Exp Med. 2020 May;20(2): 159-166. doi:10.1007/s10238-020-00606-7. Epub 2020 Mar 4.; Carpintero MF, Martinez L, Fernandez I, et al. Diagnosis and risk stratification in patients with anti-RNP autoimmunity. Lupus. 2015 Sep;24(10):1057-66. doi:10.1177/0961203315575586. Epub 2015 Mar 2.; Miyamae T, Ito S, Machida H, et al. Clinical features and laboratory findings in children with both anti-dsDNA and antiU1-RNP antibody. Nihon Rinsho Meneki Gakkai Kaishi. 2008 Oct;31(5):405-14. doi:10.2177/jsci.31.405.; Dima A, Jurcut C, Baicus C. The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease. Rheumatol Int. 2018 Jul;38(7):1169- 1178. doi:10.1007/s00296-018-4059-4; Gunnarsson R, Hetlevik SO, Lilleby V, et al. Mixed connective tissue disease. Best Pract Res Clin Rheumatol. 2016 Feb;30(1):95- 111. doi:10.1016/j.berh.2016.03.002. Epub 2016 Apr 12.; Mier RJ, Shishov M, Higgins GC, et al. Pediatric-onset mixed connective tissue disease. Rheum Dis Clin North Am. 2005 Aug;31(3): 483-96, vii. doi:10.1016/j.rdc.2005.04.002.; Cappelli S, Bellando Randone S, Martinovi D, et al. "To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum. 2012 Feb;41(4):589-98. doi:10.1016/j.semarthrit.2011.07.010. Epub 2011 Sep 29.; Tsai YY, Yang YH, Yu HH, et al. Fifteenyear experience of pediatric-onset mixed connective tissue disease. Clin Rheumatol. 2010 Jan;29(1):53-8. doi:10.1007/s10067-009-1276-y. Epub 2009 Sep 16.; Hetlevik SO, Flatø B, Rygg M, et al. Long-term outcome in juvenile-onset mixed connective tissue disease: a nationwide Norwegian study. Ann Rheum Dis. 2017 Jan; 76(1):159-165. doi:10.1136/annrheumdis2016-209522. Epub 2016 Jun 9.; Rutkowska-Sak L, Gietka P. Clinical features and outcome of mixed connective tissue disease in developmental age – observational study from one center. Reumatologia. 2019;57(6):315-319. doi:10.5114/reum.2019.91275. Epub 2019 Dec 31.; Radi M, Overbury RS. Capillaroscopy as a diagnostic tool in the diagnosis of mixed connective tissue disease (MCTD): a case report. BMC Rheumatol. 2021 Mar 19;5(1):9. doi:10.1186/s41927-021-00179-2.; Ungprasert P, Crowson CS, Chowdhary VR, et al. Epidemiology of Mixed Connective Tissue Disease, 1985-2014: A Population-Based Study. Arthritis Care Res (Hoboken). 2016 Dec;68(12):1843-1848. doi:10.1002/acr.22872. Epub 2016 Oct 1.; Elhani I, Khoy K, Mariotte D, et al. The diagnostic challenge of patients with antiU1-RNP antibodies. Rheumatol Int. 2023 Mar;43(3):509-521. doi:10.1007/s00296-022- 05161-w. Epub 2022 Jul 27.; Isenberg D. Thirty years, five hundred patients: some lessons learned from running a lupus clinic. Lupus. 2010 May;19(6):667-74. doi:10.1177/0961203309358600. Epub 2010 Feb 23.; Amigues JM, Cantagrel A, Abbal M, Mazieres B. Comparative study of 4 diagnosis criteria sets for mixed connective tissue disease in patients with anti-RNP antibodies. Autoimmunity Group of the Hospitals of Toulouse. J Rheumatol. 1996 Dec;23(12): 2055-62.; Chojnowski MM, Felis-Giemza A, Olesinska M. Capillaroscopy – a role in modern rheumatology. Reumatologia. 2016;54(2):67-72. doi:10.5114/reum.2016.60215. Epub 2016 Jun 3.; Felis-Giemza A, Kontny E, Haladyj E, et al. Early nailfold capillaroscopic pattern predominates in patients with mixed connective tissue disease. Ann Rheum Dis. 2016;75:738.; Markusse IM, Meijs J, de Boer B, et al. Predicting cardiopulmonary involvement in patients with systemic sclerosis: complementary value of nailfold videocapillaroscopy patterns and disease-specific autoantibodies. Rheumatology (Oxford). 2017 Jul 1;56(7): 1081-1088. doi:10.1093/rheumatology/ kew402.; Pavlov-Dolijanovic S, Damjanov NS, Stojanovic RM, et al. Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow-up study of 3,029 patients with primary Raynaud's phenomenon. Rheumatol Int. 2012 Oct;32(10):3039-45. doi:10.1007/s00296-011-2109-2. Epub 2011 Sep 8.; Celinska-Löwenhoff M, Pastuszczak M, Pelka K, et al. Associations between nailfold capillaroscopy findings and interstitial lung disease in patients with mixed connective tissue disease. Arch Med Sci. 2019 Jan 11; 16(2):297-301. doi:10.5114/aoms.2018. 81129. eCollection 2020.; Tiddens HA, van der Net JJ, de GraeffMeeder ER, et al. Juvenile-onset mixed connective tissue disease: longitudinal follow-up. J Pediatr. 1993 Feb;122(2):191-7. doi:10.1016/s0022-3476(06)80112-5.; Jovancevic B, Lindholm C, Pullerits R. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature. Lupus. 2013 Jun;22(7):664-74. doi:10.1177/0961203313485489. Epub 2013 Apr 23.; Mankikian J, Caille A, Reynaud-Gaubert M, et al; EVER-ILD investigators and the OrphaLung network. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. Eur Respir J. 2023 Jun 8;61(6): 2202071. doi:10.1183/13993003.02071-2022. Print 2023 Jun.; Haroon M, O'Gradaigh D, Foley-Nolan D. A case of Raynaud's phenomenon in mixed connective tissue disease responding to rituximab therapy. Rheumatology (Oxford). 2007 Apr;46(4):718-9. doi:10.1093/rheumatology/kem003. Epub 2007 Feb 8.; Rudolph SE, Kouba M, Hrdlicka P. Severe corticoid-refractory autoimmune thrombocytopenia associated with mixed connective tissue disease (Sharp's syndrome). Treatment with rituximab. Dtsch Med Wochenschr. 2009 Sep;134(36):1734-8. doi:10.1055/s-0029-1234008. Epub 2009 Aug 28.; Brunner HI, Wong R, Nys M, et al; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis. Paediatr Drugs. 2020 Dec;22(6):653-672. doi:10.1007/s40272-020-00422-2. Epub 2020 Oct 8.; Curiel RV, Nguyen W, Mamyrova G, et al; Abatacept in Dermatomyositis (AID) Trial Investigators. Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy. Arthritis Rheumatol. 2023 Jul;75(7):1229-1237. doi:10.1002/art.42450. Epub 2023 Jun 7.; Castellvi I, Elhai M, Bruni C, et al; for EUSTAR network. Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience. Semin Arthritis Rheum. 2020 Dec; 50(6):1489-1493. doi:10.1016/j.semarthrit.2019.12.004; Ikeda K, Sanayama Y, Makita S, et al. Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus. Clin Dev Immunol. 2013:2013:697525. doi:10.1155/2013/697525. Epub 2013 Nov 14.; Rodina Y, Deripapa E, Shvets O, et al. Rituximab and Abatacept Are Effective in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies. Front Immunol. 2021 Sep 9:12:704261. doi:10.3389/fimmu.2021.704261. eCollection 2021.; Каледа МИ, Никишина ИП, Латыпова АН. Опыт диагностики и лечения синдрома Шегрена у детей. Педиатрия. Журнал им. Г.Н. Сперанского. 2019; 98(3):74-82.; Каледа МИ, Никишина ИП, Салугина СО и др. Ювенильные идиопатические воспалительные миопатии: результаты открытого одноцентрового ретроспективного исследования. Современная ревматология. 2022;16(4):32-39. doi:10.14412/1996-7012-2022-4-32-39; https://mrj.ima-press.net/mrj/article/view/1533

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1533
https://doi.org/10.14412/1996-7012-2024-1-62-69

المؤلفون: М. Павлова, М. Виденова, И.Н. Иванов, В. Велев, М. Попов

المصدر: University Therapeutic Journal, Vol 5, Iss 3 (2023)

مصطلحات موضوعية: диареегенные E. coli, чувствительность к антибиотикам, фекальные носители, ранний детский возраст, Medicine

وصف الملف: electronic resource

Relation: https://www.ojs3.gpmu.org/index.php/Un-ther-journal/article/view/5796; https://doaj.org/toc/2713-1912; https://doaj.org/toc/2713-1920

URL الوصول: https://doaj.org/article/f3bee19cbd25488595808fb83e916826

المؤلفون: M. I. Kaleda, I. P. Nikishina, S. O. Salugina, E. S. Fedorov, S. V. Arsenyeva, A. N. Shapovalenko, T. N. Pachkoria, V. G. Matkava

المصدر: Современная ревматология, Vol 16, Iss 4, Pp 32-39 (2022)

مصطلحات موضوعية: детский возраст, ювенильные идиопатические воспалительные миопатии, ювенильный дерматомиозит, overlapмиозит, Medicine

وصف الملف: electronic resource

Relation: https://mrj.ima-press.net/mrj/article/view/1320; https://doaj.org/toc/1996-7012; https://doaj.org/toc/2310-158X

URL الوصول: https://doaj.org/article/802559bbc4eb4aa98dd723665e3e0220

المؤلفون: O. M. Davidian, A. V. Fomina, E. A. Lukianova, E. M. Shimkevich, Ju. A. Bakaev, K. O. Tikhonova, D. M. Todua

المصدر: Эндодонтия Today, Vol 19, Iss 4, Pp 285-292 (2021)

مصطلحات موضوعية: распространенность кариеса, интенсивность кариеса, ранний детский кариес, ранний детский возраст, антенатальные факторы риска, постнатальные факторы риска, анкетирование, Dentistry, RK1-715

وصف الملف: electronic resource

Relation: https://www.endodont.ru/jour/article/view/1018; https://doaj.org/toc/1683-2981; https://doaj.org/toc/1726-7242

URL الوصول: https://doaj.org/article/fd450325813e4d2ba20d931160bffd48

المؤلفون: Мавлянова, Зилола Фархадовна, Хайдарова, Сарвиноз Хайдаржоновна

المصدر: Science and Education; Vol. 4 No. 2 (2023): Science and Education; 328-337 ; 2181-0842

مصطلحات موضوعية: детский возраст, хронический бронхит, клиника, диагностика, лечение

وصف الملف: application/pdf

Relation: https://openscience.uz/index.php/sciedu/article/view/5040/4620; https://openscience.uz/index.php/sciedu/article/view/5040

الاتاحة: https://openscience.uz/index.php/sciedu/article/view/5040

المؤلفون: V. V. Evreinov, E. A. Raznoglyadova, В. В. Евреинов, Е. А. Разноглядова

المصدر: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 67, № 6 (2022); 58-62 ; Российский вестник перинатологии и педиатрии; Том 67, № 6 (2022); 58-62 ; 2500-2228 ; 1027-4065

مصطلحات موضوعية: деформация костей скелета, spinal muscular atrophy, childhood, comorbid pathology, skeletal deformity, спинальная мышечная атрофия, детский возраст, коморбидная патология

وصف الملف: application/pdf

Relation: https://www.ped-perinatology.ru/jour/article/view/1743/1323; Kolb S.J., Kissel J.T. Spinal Muscular Atrophy. Neurol Clin 2015; 33(4): 831–846. DOI:10.1016/j.ncl.2015.07.004; Mercuri E., Finkel R.S., Muntoni F., Wirth B., Montes J., Main M. et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord 2018; 28(2): 103–115. DOI:10.1016/j.nmd.2017.11.005; Wirth B., Karakaya M., Kye M.J., Mendoza-Ferreira N. Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next. Annu Rev Genomics Hum Genet 2020; 21: 231–261. DOI:10.1146/annurev-genom-102319–103602; Vu-Han T.L., Reisener M.J., Putzier M., Pumberger M. Scoliosis in spinal muscular atrophy. Orthopade 2021; 50(8): 657–663. DOI:10.1007/s00132–021–04131–7; Salazar R., Montes J., Young S.D., McDermott M.P., Martens W., Pasternak A. et al. Quantitative evaluation of lower extremity joint contractures in spinal muscular atrophy: implications for motor function. Pediatr Phys Ther 2018; 30(3): 209–215. DOI:10.1097/PEP.0000000000000515; Guo W.H., Cao L., Chang L. Clinical characteristics of non-invasive ventilation treatment in children with spinal muscular atrophy and sleep disordered breathing. Zhonghua Er Ke Za Zhi 2019; 2;57(10): 792–796. DOI:10.3760/cma.j.issn.0578–1310.2019.10.012; Грознова О.С., Руденская Г.Е., Адян Т.А., Харламов Д.А.Поражение сердца при наследственных нервно-мышечных заболеваниях у детей. Российский вестник перинатологии ипедиатрии 2014; 2:35–42.; Maxwell G.K., Szunyogova E., Shorrock H.K., Gillingwater T.H., Parson S.H. Developmental and degenerative cardiac defects in the Taiwanese mouse model of severe spinal muscular atrophy. J Anat 2018; 232(6): 965–978. DOI:10.1111/joa.12793; WÜngaarde C.A., Blank A.C., Stam M., Wadman R.I., Berg L.H., Pol W.L. Cardiac pathology in spinal muscular atrophy: a systematic review. Orphanet J Rare Dis 2017; 12: 67. DOI:10.1186/s13023–017–0613–5; Deguise M.O., Chehade L., Kothary R. Metabolic dysfunction in spinal muscular atrophy. Int J Mol Scie 2021; 22(11): 5913. DOI:10.3390/Ùms22115913; Deguise M.O., Baranello G., Mastella C., Beauvais A., Michaud J., Leone A. et al. Abnormal fatty acid metabolism is a core component of spinal muscular atrophy. Ann Clin Transl Neurol 2019; 6(8): 1519–1532. DOI:10.1002/acn3.50855; Szunyogova E., Zhou H., Maxwell G.K., Powis R.A., Muntoni F., Gillingwater T.H. et al. Survival Motor Neuron (SMN) protein is required for normal mouse liver development. Scientific Reports 2016; 6: 34635. DOI:10.1038/srep34635; WÜngaarde C.A., Huisman A., Wadman R.I., Cuppen I., Stam M., Heitink-Pollé K.M.J. et al. Abnormal coagulation parameters are a common non-neuromuscular feature in patients with spinal muscular atrophy. J Neurol Neurosurg Psychiatry 2020; 91(2): 212–214. DOI:10.1136/jnnp-2019–321506; De Wel B., Goosens V., Sobota A., Van Camp E., Geukens E., Van Kerschaver G. et al. Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4. J Neurol 2021; 268(3): 923–935. DOI:10.1007/s00415–020–10223–9; Pera M.C., Coratti G., Forcina N., Mazzone E.S., Scoto M., Montes J. et al. Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy. BMC Neurol 2017; 17: 39. DOI:10.1186/s12883–017–0790–9; McGrattan K.E., Graham R.J., DiDonato C.J., Darras B.T. Dysphagia phenotypes in spinal muscular atrophy: the past, present, and promise for the future. Am J Speech Lang Pathol 2021; 30(3): 1008–1022. DOI:10.1044/2021_AJSLP-20–00217; Finkel R.S., Mercuri E., Meyer O.H., Simonds A.K., Schroth M.K., Graham R.J. et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscular Disorders 2018; 28(3): 197–207. DOI:10.1016/j.nmd.2017.11.004; Morris L.E.H., EstilowT., Glanzman A.M., Cusack S.V., YumS.W. Improving temporomandibular range of motion in people with Duchenne muscular dystrophy and spinal muscular atrophy. Am J Occupat Ther 2020; 74(2): 7402205080p1–7402205080p10. DOI:10.5014/ajot.2020.030825; Yang J.H., Kasat N.S., Suh S.W., Kim S.Y. Improvement in reflux gastroesophagitis in a patient with spinal muscular atrophy after surgical correction of kyphoscoliosis: a case report. Clin Orthop Relat Res 2011; 469(12): 3501–3505. DOI:10.1007/s11999–011–2080-y; Grychtol R., Abela F., Fitzgeral D.A. The role of sleep diagnostics and non-invasive ventilation in children with spinal muscular atrophy. Paediatr Respir Rev 2018; 28: 18–25. DOI:10.1016/j.prrv.2018.07.006; Chabanon A., Seferian A.M., Daron A., Péréon Y., Cances C., Vuillerot C. et al. Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study. PLoS One 2018; 13(7): e0201004. DOI:10.1371/journal.pone.0201004; Djordjevic S.A., Milic-Rasic V., Brankovic V., Kosac A., Vukomanovic G., Topalovic M. et al. Cardiac findings in pediatric patients with spinal muscular atrophy types 2 and 3. Muscle Nerve 2021; 63(1): 75–83. DOI:10.1002/mus.27088; Alves C.R.R., Zhang R., Johnstone A.J., Garner R., Nwe P.H., Siranosian J.J. et al. Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy. Neurology 2020; 94(9): e921–e931. DOI:10.1212/WNL.0000000000008762; Freigang M., Wurster C.D., Hagenacker T., Stolte B., Weiler M., Kamm C. et al. Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment. Ann Clin Transl Neurol 2021; 8(5): 1049–1063. DOI:10.1002/acn3.51340; Pino M.G., Rich K.A., Kolb S.J. Update on Biomarkers in Spinal Muscular Atrophy. Biomark Insights 2021; 16: 11772719211035643. DOI:10.1177/11772719211035643; https://www.ped-perinatology.ru/jour/article/view/1743

الاتاحة: https://www.ped-perinatology.ru/jour/article/view/1743
https://doi.org/10.21508/1027-4065-2022-67-6-58-6

المؤلفون: M. I. Kaleda, I. P. Nikishina, М. И. Каледа, И. П. Никишина

المساهمون: Статья подготовлена в рамках фундаментального научного исследования по теме «Выявление клинических фенотипов и прогнозирование вариантов течения аутоиммунных и аутовоспалительных ревматических заболеваний детского возраста» FURS-2022-0001, регистрационный номер в ЕГИСУ 1021051302580-4.

المصدر: Rheumatology Science and Practice; Vol 61, No 6 (2023); 639-649 ; Научно-практическая ревматология; Vol 61, No 6 (2023); 639-649 ; 1995-4492 ; 1995-4484

مصطلحات موضوعية: детский возраст, systemic lupus erythematosus with juvenile onset, systemic sclerosis with juvenile onset, juvenile dermatomyositis, childhood, системная красная волчанка с ювенильным началом, системный склероз с ювенильным началом, ювенильный дерматомиозит

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3469/2329; Tarvin SE, O’Neil KM, Systemic lupus erythematosus, Sjögren syndrome, and mixed connective tissue disease in children and adolescents. Pediatr Clin North Am. 2018;65(4):711-737. doi:10.1016/j.pcl.2018.04.001; Klemperer P, Pollack AD, Baehr G. Diffuse collagen disease. Arch Path. 1941;32:569-591.; Сигидин ЯА, Иванова ММ, Гусева НГ. Диффузные болезни соединительной ткани (системные ревматические заболевания). Руководство для врачей. М.:Медицина;1994.; Лыскина Г.А. Проблемы системных заболеваний соединительной ткани у детей. Педиатрия. Журнал им. Г.Н. Сперанского. 2004;2:46-52.; McGonagle D, Aziz A, Dickie LJ, McDermott MF. An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum. Pediatr Res. 2009;65(5 Pt 2):38R-45R. doi:10.1203/PDR.0b013e31819dbd0a; Cui Y, Sheng Y, Zhang X. Genetic susceptibility to SLE: Recent progress from GWAS. J Autoimmun. 2013;41:25-33. doi:10.1016/j.jaut.2013.01.008; Smith EMD, Lythgoe H, Midgley A, Beresford MW, Hedrich CM. Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. Clin Immunol. 2019;209:108274. doi:10.1016/j.clim.2019.108274; Alexander T, Hedrich CM. Systemic lupus erythematosus – Are children miniature adults? Clin Immunol. 2022;234:108907. doi:10.1016/j.clim.2021.108907; Асеева ЕА, Лила АМ, Соловьев СК, Насонов ЕЛ, Глухова СИ. Клинико-иммунологические фенотипы системной красной волчанки, выделенные на основании кластерного анализа данных 400 пациентов ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой». Современная ревматология. 2022;16(5):13-21. doi:10.14412/1996-7012-2022-5-13-21; Groot N, Shaikhani D, Teng YKO, de Leeuw K, Bijl M, Dolhain RJEM, et al. Long-term clinical outcomes in a cohort of adults with childhood-onset systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(2):290-301. doi:10.1002/art.40697; Levy DM, Kamphuis S. Systemic lupus erythematosus in children and adolescents. Pediatr Clin North Am. 2012;59(2):345-364. doi:10.1016/j.pcl.2012.03.007; Huang JL, Yao TC, See LC. Prevalence of pediatric systemic lupus erythematosus and juvenile chronic arthritis in a Chinese population: A nation-wide prospective population-based study in Taiwan. Clin Exp Rheumatol. 2004;22:776-780.; Hedrich CM, Smith EMD, Beresford MW. Juvenile-onset systemic lupus erythematosus (jSLE) – Pathophysiological concepts and treatment options. Best Pract Res Clin Rheumatol. 2017;31(4):488-504. doi:10.1016/j.berh.2018.02.001; Ardoin SP, Daly RP, Merzoug L, Tse K, Ardalan K, Arkin L, et al.; Childhood Arthritis and Rheumatology Research Alliance and Lupus Foundation of America. Research priorities in childhood -onset lupus: Results of a multidisciplinary prioritization exercise. Pediatr Rheumatol Online J. 2019;17(1):32. doi:10.1186/s12969-019-0327-4; Appenzeller S, Pereira DR, Julio PR, Reis F, Rittner L, Marini R. Neuropsychiatric manifestations in childhood-onset systemic lupus erythematosus. Lancet Child Adolesc Health. 2022;6(8):571-581. doi:10.1016/S2352-4642(22)00157-2; Natoli V, Charras A, Hahn G, Hedrich CM. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus (jSLE). Mol Cell Pediatr. 2023;10(1):5. doi:10.1186/s40348-023-00161-7; Каледа МИ, Никишина ИП, Глухова СИ, Степаненко НЮ. Нейропсихические нарушения при ювенильном дебюте системной красной волчанки: результаты ретроспективного исследования. Научно-практическая ревматология. 2020;58(2):171-177. doi:10.14412/1995-4484-2020-171-177; Yu H, Nagafuchi Y, Fujio K. Clinical and immunological biomarkers for systemic lupus erythematosus. Biomolecules. 2021;11(7):928. doi:10.3390/biom11070928; Caielli S, Wan Z, Pascual V. Systemic lupus erythematosus pathogenesis: Interferon and beyond. Annu Rev Immunol. 2023;41:533-560. doi:10.1146/annurev-immunol-101921-042422; Li H, Wang T, Li B, Huang T, Hai Y, Huang C, et al. Bioinformatic analysis of immune-related transcriptome affected by IFIT1 gene in childhood systemic lupus erythematosus. Transl Pediatr. 2023;12(8):1517-1526. doi:10.21037/tp-23-365; Sestan M, Kifer N, Arsov T, Cook M, Ellyard J, Vinuesa CG, et al. The role of genetic risk factors in pathogenesis of childhoodonset systemic lupus erythematosus. Curr Issues Mol Biol. 2023;45(7):5981-6002. doi:10.3390/cimb45070378; Massias JS, Smith EMD, Al-Abadi E, Armon K, Bailey K, Ciurtin C, et al. Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. Lupus. 2020;29(5):474-481. doi:10.1177/0961203320909156; Massias JS, Smith EM, Al-Abadi E, Armon K, Bailey K, Ciurtin C, et al. Clinical and laboratory phenotypes in juvenile-onset systemic lupus erythematosus across ethnicities in the UK. Lupus. 2021;30(4):597-607. doi:10.1177/0961203320984251; Lythgoe H, Lj M, Hedrich CM, Aringer M. Classification of systemic lupus erythematosus in children and adults. Clin Immunol. 2022;234:108898. doi:10.1016/j.clim.2021.108898; Chang LS, Huang PY, Kuo HC, Tu YK, Tseng PT, Liang CS, et al. Diagnostic accuracy of the American College of Rheumatology-1997, the Systemic Lupus International Collaborating Clinics-2012, and the European League Against Rheumatism-2019 criteria for juvenile systemic lupus erythematosus: A systematic review and network meta-analysis. Autoimmun Rev. 2022;21(9):103144. doi:10.1016/j.autrev.2022.103144; Falcini F, Nacci F. Systemic lupus erythematosus in the young: The importance of a transition clinic. Lupus. 2007;16(8):613-617. doi:10.1177/0961203307078973; Alperin JM, Ortiz-Fernández L, Sawalha AH. Monogenic lupus: A developing paradigm of disease. Front Immunol. 2018;9:2496. doi:10.3389/fimmu.2018.02496; Harley ITW, Sawalha AH. Systemic lupus erythematosus as a genetic disease. Clin Immunol. 2022;236:108953. doi:10.1016/j.clim.2022.108953; Demirkaya E, Sahin S, Romano M, Zhou Q, Aksentijevich I. New horizons in the genetic etiology of systemic lupus erythematosus and lupus-like disease: Monogenic lupus and beyond. J Clin Med. 2020;9(3):712. doi:10.3390/jcm9030712; Kim H, Sanchez GA, Goldbach-Mansky R. Insights from Mendelian interferonopathies: Comparison of CANDLE, SAVI with AGS, monogenic lupus. J Mol Med (Berl). 2016;94(10):1111-1127. doi:10.1007/s00109-016-1465-5; Nigrovic PA, Lee PY, Hoffman HM. Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach. J Allergy Clin Immunol. 2020;146(5):925-937. doi:10.1016/j.jaci.2020.08.017; Sandling JK, Pucholt P, Hultin Rosenberg L, Farias FHG, Kozyrev SV, Eloranta ML, et al. Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. Ann Rheum Dis. 2021;80(1):109-117. doi:10.1136/annrheumdis-2020-218636; Al-Mayouf SM, Alreefi HA, Alsinan TA, AlSalmi G, AlRowais A, Al-Herz W, et al. Lupus manifestations in children with primary immunodeficiency diseases: Comprehensive phenotypic and genetic features and outcome. Mod Rheumatol. 2021;31(6):1171-1178. doi:10.1080/14397595.2021.1886627; Chan SCW, Lau CS. Systemic lupus erythematosus and immunodeficiency. Rheumatol Immunol Res. 2021;2(3):131-138. doi:10.2478/rir-2021-0019; Ozturk K, Caglayan S, Tanatar A, Baglan E, Yener Otar G, Kavrul Kayaalp G, et al.; PeRA-Research Group. Low disease activity state in juvenile-onset systemic lupus erythematosus. Lupus. 2021;30(13):2144-2150. doi:10.1177/09612033211054399; Nakorn K, Piyaphanee N, Sukharomana M, Pinpatanapong R, Charuvanij S. Outcomes of achieving lupus low disease activity state and damage accrual in childhood-onset systemic lupus erythematosus. Clin Rheumatol. 2023;42(6):1655-1664. doi:10.1007/s10067-023-06533-8; Groot N, de Graeff N, Avcin T, Bader-Meunier B, Brogan P, Dolezalova P, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: The SHARE initiative. Ann Rheum Dis. 2017;76(11):1788-1796. doi:10.1136/annrheumdis-2016-210960; Gutiérrez-Suárez R, Ruperto N, Gastaldi R, Pistorio A, Felici E, Burgos-Vargas R, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 2006;54(9):2989-2996. doi:10.1002/art.22048; Blamires J, Foster M, Napier S, Dickinson A. Experiences and perspectives of children and young people living with childhood -onset systemic lupus erythematosus – An integrative review. Children (Basel). 2023;10(6):1006. doi:10.3390/children10061006; Zulian F. Scleroderma in children. Best Pract Res Clin Rheumatol. 2017;31(4):576-595. doi:10.1016/j.berh.2018.02.004; Herrick AL, Ennis H, Bhushan M, Silman AJ, Baildam EM. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res (Hoboken). 2010;62(2):213-218. doi:10.1002/acr.20070; Beukelman T, Xie F, Foeldvari I. Assessing the prevalence of juvenile systemic sclerosis in childhood using administrative claims data from the United States. J Scleroderma Relat Disord. 2018;3(2):189-190. doi:10.1177/2397198318763701; Martini G, Vittadello F, Kasapçopur O, Magni Manzoni S, Corona F, Duarte-Salazar C, et al.; Juvenile Scleroderma Working Group of Paediatric Rheumatology European Society (PRES). Factors affecting survival in juvenile systemic sclerosis. Rheumatology (Oxford). 2009;48(2):119-222. doi:10.1093/rheumatology/ken388; Valeur NS, Stevens AM, Ferguson MR, Effmann EL, Iyer RS. Multimodality thoracic imaging of juvenile systemic sclerosis: Emphasis on clinical correlation and high-resolution CT of pulmonary fibrosis. AJR Am J Roentgenol. 2015;204(2):408-422. doi:10.2214/AJR.14.12461; Li SC. Scleroderma in children and adolescents: Localized scleroderma and systemic sclerosis. Pediatr Clin North Am. 2018;65(4):757-781. doi:10.1016/j.pcl.2018.04.002; Scalapino K, Arkachaisri T, Lucas M, Fertig N, Helfrich DJ, Londino AV Jr, et al. Childhood onset systemic sclerosis: Classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol. 2006;33(5):1004-1013.; Rutkowska-Sak L, Gietka P, Gazda A, Kołodziejczyk B. Juvenile systemic sclerosis – observations of one clinical centre. Reumatologia. 2021;59(6):367-372. doi:10.5114/reum.2021.112350; Céspedes-Cruz AI, Carranza-Muleiro RA, López-Rojas EL, Cruz-Domínguez MP, Espinosa-Gan H, Ramírez-Pérez J, et al. Pulmonary involvement in patients with juvenile systemic sclerosis. Bol Med Hosp Infant Mex. 2021;78(5):385-394. doi:10.24875/BMHIM.20000301; Foeldvari I, Klotsche J, Hinrichs B, Helmus N, Kasapcopur O, Adrovic A, et al. Underdetection of interstitial lung disease in juvenile systemic sclerosis. Arthritis Care Res (Hoboken). 2022;74(3):364-370. doi:10.1002/acr.24499; Apitz C, Girschick H. Systemic sclerosis-associated pulmonary arterial hypertension in children. Cardiovasc Diagn Ther. 2021;11(4):1137-1143. doi:10.21037/cdt-20-901; Adrovic A, Karatemiz G, Esatoglu SN, Yildiz M, Sahin S, Barut K, et al. Juvenile and adult-onset scleroderma: Different clinical phenotypes. Semin Arthritis Rheum. 2023;60:152197. doi:10.1016/j.semarthrit.2023.152197; Foeldvari I, Klotsche J, Torok KS, Kasapcopur O, Adrovic A, Stanevicha V, et al. Are diffuse and limited juvenile systemic sclerosis different in clinical presentation? Clinical characteristics of a juvenile systemic sclerosis cohort. J Scleroderma Relat Disord. 2019;4(1):49-61. doi:10.1177/2397198318790494; Foeldvari I, Klotsche J, Kasapcopur O, Adrovic A, Terreri MT, Sakamoto AP, et al. Gender differences in juvenile systemic sclerosis patients: Results from the international juvenile scleroderma inception cohort. J Scleroderma Relat Disord. 2023;8(2):120-130. doi:10.1177/23971983221143244; Stevens AM, Torok KS, Li SC, Taber SF, Lu TT, Zulian F. Immunopathogenesis of juvenile systemic sclerosis. Front Immunol. 2019;10:1352. doi:10.3389/fimmu.2019.01352; Zulian F, Woo P, Athreya BH, Laxer RM, Medsger TA Jr, Lehman TJ, et al. The Pediatric Rheumatology European Society/ American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum. 2007;57(2):203-212. doi:10.1002/art.22551; van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747-1755. doi:10.1136/annrheumdis-2013-204424; Martini G, Foeldvari I, Russo R, Cuttica R, Eberhard A, Ravelli A, et al.; Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society. Systemic sclerosis in childhood: Clinical and immunologic features of 153 patients in an international database. Arthritis Rheum. 2006;54(12):3971-3978. doi:10.1002/art.22207; Foeldvari I, Culpo R, Sperotto F, Anton J, Avcin T, Baildam E, et al. Consensus-based recommendations for the management of juvenile systemic sclerosis. Rheumatology (Oxford). 2021;60(4):1651-1658. doi:10.1093/rheumatology/keaa584; Klotsche J, Torok KS, Kasapcopur O, Adrovic A, Terreri MT, Sakamoto AP, et al. Application and performance of disease activity indices proposed for patients with systemic sclerosis in an international cohort of patients with juvenile systemic sclerosis. J Scleroderma Relat Disord. 2023;8(3):183-191. doi:10.1177/23971983231164700; Beukelman T, Xie F, Foeldvari I. The prevalence of localised scleroderma in childhood assessed in the administrative claims data from the United States. J Scleroderma Relat Disord. 2019;4(1): 77-78. doi:10.1177/2397198318798588; Zulian F, Vallongo C, Woo P, Russo R, Ruperto N, Harper J, et al.; Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society (PRES). Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005;52(9):2873-2881. doi:10.1002/art.21264; Papadopoulou C, Chew C, Wilkinson MGL, McCann L, Wedderburn LR. Juvenile idiopathic inflammatory myositis: An update on pathophysiology and clinical care. Nat Rev Rheumatol. 2023;19(6):343-362. doi:10.1038/s41584-023-00967-9; Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J. Incidence and prevalence of inflammatory myopathies: A systematic review. Rheumatology (Oxford). 2015;54(1):50-63. doi:10.1093/rheumatology/keu289; Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, et al.; with the Childhood Myositis Heterogeneity Collaborative Study Group. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(1):25-41. doi:10.1097/MD.0b013e31827f264d; Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken). 2010;62(1):63-72. doi:10.1002/acr.20015; Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med. 2016;280(1):24-38. doi:10.1111/joim.12444; Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, et al.; Childhood Myositis Heterogeneity Study Group. Association of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies with DRB1*07:01 and severe myositis in juvenile myositis patients. Arthritis Care Res (Hoboken). 2017;69(7):1088-1094. doi:10.1002/acr.23113; Li D, Tansley SL. Juvenile dermatomyositis – Clinical phenotypes. Curr Rheumatol Rep. 2019;21(12):74. doi:10.1007/s11926-019-0871-4; Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: Significance of early clinical and laboratory features. Arthritis Rheum. 2008;58(11):3585-3592. doi:10.1002/art.23960; Каледа МИ, Никишина ИП, Салугина СО, Федоров ЕС, Арсеньева СВ, Шаповаленко А.Н., и др. Ювенильные идиопатические воспалительные миопатии: результаты открытого одноцентрового ретроспективного исследования. Современная ревматология. 2022;16(4):32-39. doi:10.14412/1996-7012-2022-4-32-39; Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton R, et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr. 2006;148(2):247-253. doi:10.1016/j.jpeds.2005.10.032; Gitiaux C, De Antonio M, Aouizerate J, Gherardi RK, Guilbert T, Barnerias C, Bodemer C, et al. Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis. Rheumatology (Oxford). 2016;55(3):470-479. doi:10.1093/rheumatology/kev359; Papadopoulou C, Hong Y, Krol P, Al Obaidi M, Pilkington C, Wedderburn LR, et al. The vasculopathy of juvenile dermatomyositis: Endothelial injury, hypercoagulability, and increased arterial stiffness. Arthritis Rheumatol. 2021;73(7):1253-1266. doi:10.1002/art.41639; McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, Murray KJ, et al.; Juvenile Dermatomyositis Research Group. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland) – Clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford). 2006; 45(10):1255-1260. doi:10.1093/rheumatology/kel099; Sanner H, Aaløkken TM, Gran JT, Sjaastad I, Johansen B, Flatø B. Pulmonary outcome in juvenile dermatomyositis: A case-control study. Ann Rheum Dis. 2011;70(1):86-91. doi:10.1136/ard.2010.131433; Orandi AB, Baszis KW, Dharnidharka VR, Huber AM, Hoeltzel MF; CARRA Juvenile Myositis subgroup. Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: A survey of pediatric rheumatologists by the Childhood Arthritis and Rheumatology Research Alliance (CARRA). Pediatr Rheumatol Online J. 2017;15(1):71. doi:10.1186/s12969-017-0199-4; Mehta P, Lawrence A, Gupta L, Misra DP, Agarwal V, Misra R, et al. Long-standing and poorly controlled disease in juvenile dermatomyositis is associated with calcinosis: A real-world experience from a low-middle income country. Rheumatol Int. 2023 Jul 5. doi:10.1007/s00296-023-05377-4; Yi BY, Marrs J, Acharya P, Sura A, Cidon M. Risk factors for developing calcinosis in juvenile dermatomyositis: Subcutaneous and myofascial edema in initial magnetic resonance imaging. Rheumatol Int. 2023 Jul 11. doi:10.1007/s00296-023-05385-4; Okiyama N. Clinical features and cutaneous manifestations of juvenile and adult patients of dermatomyositis associated with myositis-specific autoantibodies. J Clin Med. 2021;10(8):1725. doi:10.3390/jcm10081725; Gerami P, Walling HW, Lewis J, Doughty L, Sontheimer RD. A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol. 2007;157(4):637-644. doi:10.1111/j.1365-2133.2007.08055.x; Mamyrova G, Kishi T, Targoff IN, Ehrlich A, Curiel RV, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group. Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. Rheumatology (Oxford). 2018; 57(11):1956-1963. doi:10.1093/rheumatology/key190; Gezgin Yıldırım D, Baglan E, Güngörer V, Yıldız C, Tuncez S, Bülbül M, et al. Comparison of clinical and laboratory features and treatment responses in patients with clinically amyopathic juvenile dermatomyositis and classical juvenile dermatomyositis. Int J Rheum Dis. 2023;26(8):1504-1511. doi:10.1111/1756-185X.14773; Xia J, Jiang G, Jin T, Shen Q, Ma Y, Wang L, et al. Respiratory symptoms as initial manifestations of interstitial lung disease in clinically amyopathic juvenile dermatomyositis: A case report with literature review. BMC Pediatr. 2021;21(1):488. doi:10.1186/s12887-021-02958-9; Kishi T, Tani Y, Okiyama N, Mizuochi K, Ichimura Y, Harigai M, et al. Anti-SAE autoantibody-positive Japanese patient with juvenile dermatomyositis complicated with interstitial lung disease – A case report. Pediatr Rheumatol Online J. 2021;19(1):34. doi:10.1186/s12969-021-00532-2; Abu-Rumeileh S, Marrani E, Maniscalco V, Maccora I, Pagnini I, Mastrolia MV, et al. Lung involvement in juvenile idiopathic inflammatory myopathy: A systematic review. Autoimmun Rev. 2023;22(10):103416. doi:10.1016/j.autrev.2023.103416; Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, et al.; Childhood Myositis Heterogeneity Collaborative Study Group. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(4):223-243. doi:10.1097/MD.0b013e31829d08f9; Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018;20(4): 21. doi:10.1007/s11926-018-0732-6; Binns EL, Moraitis E, Maillard S, Tansley S, McHugh N, Jacques TS, et al.; UK Juvenile Dermatomyositis Research Group (UK and Ireland). Effective induction therapy for anti-SRP associated myositis in childhood: A small case series and review of the literature. Pediatr Rheumatol Online J. 2017;15(1):77. doi:10.1186/s12969-017-0205-x; Wedderburn LR, McHugh NJ, Chinoy H, Cooper RG, Salway F, Ollier WE, et al.; Juvenile Dermatomyositis Research Group (JDRG). HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford). 2007;46(12):1786-1791. doi:10.1093/rheumatology/kem265; Bitencourt N, Solow EB, Wright T, Bermas BL. Inflammatory myositis in systemic lupus erythematosus. Lupus. 2020;29(7):776-781. doi:10.1177/0961203320918021; Martin N, Krol P, Smith S, Murray K, Pilkington CA, Davidson JE, et al.; Juvenile Dermatomyositis Research Group. A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years’ experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. Rheumatology (Oxford). 2011;50(1):137-145. doi:10.1093/rheumatology/keq261; Moneta GM, Pires Marafon D, Marasco E, Rosina S, Verardo M, Fiorillo C, et al. Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features. Arthritis Rheumatol. 2019;71(6):1011-1021. doi:10.1002/art.40800; Wilkinson MGL, Radziszewska A, Wincup C, Ioannou Y, Isenberg DA, Manson JJ, et al. Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies. Rheumatology (Oxford). 2020;59(1):194-204. doi:10.1093/rheumatology/kez252; Piper CJM, Wilkinson MGL, Deakin CT, Otto GW, Dowle S, Duurland CL, et al. CD19+CD24hiCD38hi B cells are expanded in juvenile dermatomyositis and exhibit a pro-inflammatory phenotype after activation through Toll-like receptor 7 and interferon-α. Front Immunol. 2018;9:1372. doi:10.3389/fimmu.2018.01372; Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403-407.; Brown VE, Pilkington CA, Feldman BM, Davidson JE; Network for juvenile dermatomyositis, Paediatric Rheumatology European Society (PReS). An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford). 2006;45(8):990-993. doi:10.1093/rheumatology/kel025; Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al.; International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017;69(12):2271-2282. doi:10.1002/art.40320; Patel B, Khan N, Werth VP. Applicability of EULAR/ACR classification criteria for dermatomyositis to amyopathic disease. J Am Acad Dermatol. 2018;79(1):77-83.e1. doi:10.1016/j.jaad.2017.12.055; Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329-340. doi:10.1136/annrheumdis-2016-209247; Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/ Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBM-FRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S118-S157. doi:10.1002/acr.20532; Gebreamlak A, Sawicka KM, Garrett R, Goh YI, Baker KM, Feldman BM. Currently recommended skin scores correlate highly in the assessment of patients with juvenile dermatomyositis (JDM). Pediatr Rheumatol Online J. 2023;21(1):63. doi:10.1186/s12969-023-00844-5; Gargh K, Al-Abadi E, Low S, Harrison K, Coles W, Davis P, et al. Juvenile Dermatomyositis Magnetic Resonance Imaging Score (JIS) does not correlate with criteria for clinically inactive disease: A single-centre retrospective evaluation. Rheumatol Int. 2022;42(7):1221-1226. doi:10.1007/s00296-021-05049-1; Kobayashi I, Akioka S, Kobayashi N, Iwata N, Takezaki S, Nakaseko H, et al. Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update. Mod Rheumatol. 2020;30(3):411-423. doi:10.1080/14397595.2020.1718866; Хелковская-Сергеева АН, Ананьева ЛП, Казаков ДО, Насонов ЕЛ. Применение магнитно-резонансной томографии в диагностике идиопатических воспалительных миопатий. Современная ревматология. 2019;13(1):95-100. doi:10.14412/1996-7012-2019-1-95-100; Gao W, Yuan C, Zou Y, Lin H. Development and pilot testing a self-reported pediatric PROMIS app for young children aged 5–7 years. J Pediatr Nurs. 2020;53:74-83. doi:10.1016/j.pedn.2020.04.003; Patel REV, Lai J-S, Gray E, Chang R, Cella D, Ardalan K. Comparison of PROMIS computerized adaptive testing administered item banks vs fixed short forms in juvenil myositis. Arthritis Rheum. 2019;71(10):abstract #433.; Li YR, Li J, Zhao SD, Bradfield JP, Mentch FD, Maggadottir SM, et al. Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases. Nat Med. 2015;21(9):1018-1027. doi:10.1038/nm.3933; Molano-González N, Rojas M, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Rodríguez Y, et al. Cluster analysis of autoimmune rheumatic diseases based on autoantibodies. New insights for polyautoimmunity. J Autoimmun. 2019;98:24-32. doi:10.1016/j.jaut.2018.11.002; Malagón C, Gomez MDP, Mosquera C, Vargas C, Gonzalez T, Arango C, et al. Juvenile polyautoimmunity in a rheumatology setting. Autoimmun Rev. 2019;18(4):369-381. doi:10.1016/j.autrev.2018.11.006; Anaya JM, Rojas-Villarraga A, Mantilla RD, Arcos-Burgos M, Sarmiento-Monroy JC. Polyautoimmunity in Sjögren syndrome. Rheum Dis Clin North Am. 2016;42(3):457-472. doi:10.1016/j.rdc.2016.03.005; Каледа МИ, Никишина ИП, Латыпова АН. Синдром Шегрена с дебютом в детском возрасте. Терапевтический архив. 2019; 91(5):54-60. [Kaleda MI, Nikishina IP, Latypova AN. Sjögren’s syndrome with juvenile onset. Terapevticheskii arkhiv. 2019; 91(5):54-60 (In Russ.)]. doi:10.26442/00403660.2019.05.000189; Groot N, de Graeff N, Marks SD, Brogan P, Avcin T, Bader-Meunier B, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: The SHARE initiative. Ann Rheum Dis. 2017;76(12):1965-1973. doi:10.1136/annrheumdis-2017-211898; Ramaswamy M, Tummala R, Streicher K, Nogueira da Costa A, Brohawn PZ. The pathogenesis, molecular mechanisms, and therapeutic potential of the interferon pathway in systemic lupus erythematosus and other autoimmune diseases. Int J Mol Sci. 2021;22(20):11286. doi:10.3390/ijms222011286; Насонов ЕЛ, Решетняк ТМ, Соловьев СК, Попкова ТВ. Системная красная волчанка и антифосфолипидный синдром: вчера, сегодня, завтра. Терапевтический архив. 2023; 95(5):365-374. doi:10.26442/00403660.2023.05.202246; Jansson AF, Sengler C, Kuemmerle-Deschner J, Gruhn B, Kranz AB, Lehmann H, et al. B cell depletion for autoimmune diseases in paediatric patients. Clin Rheumatol. 2011;30(1):87-97. doi:10.1007/s10067-010-1630-0; Werner A, Schäfer S, Zaytseva O, Albert H, Lux A, Krištić J, et al. Targeting B cells in the pre-phase of systemic autoimmunity globally interferes with autoimmune pathology. iScience. 2021;24(9):103076. doi:10.1016/j.isci.2021.103076; Merino-Vico A, Frazzei G, van Hamburg JP, Tas SW. Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches. Eur J Immunol. 2023;53(1):e2149675. doi:10.1002/eji.202149675; Welzel T, Winskill C, Zhang N, Woerner A, Pfister M. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology – What we know and what we do not know from randomized controlled trials. Pediatr Rheumatol Online J. 2021;19(1):46. doi:10.1186/s12969-021-00514-4; Насонов ЕЛ, Бекетова ТВ, Ананьева ЛП, Васильев ВИ, Соловьев СК, Авдеева АС. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40. doi:10.14412/1995-4484-2019-3-40; Mahmoud I, Jellouli M, Boukhris I, Charfi R, Ben Tekaya A, Saidane O, et al. Efficacy and safety of rituximab in the management of pediatric systemic lupus erythematosus: A systematic review. J Pediatr. 2017;187:213-219.e2. doi:10.1016/j.jpeds.2017.05.002; Sawhney S, Agarwal M. Rituximab use in pediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort. Lupus. 2021;30(11):1829-1836. doi:10.1177/09612033211034567; Zulian F, Dal Pozzolo R, Meneghel A, Castaldi B, Marcolongo R, Caforio ALP, et al. Rituximab for rapidly progressive juvenile systemic sclerosis. Rheumatology (Oxford). 2020;59(12):3793-3797. doi:10.1093/rheumatology/keaa193; Marrani E, Abu-Rumeileh S, Mastrolia MV, Maccora I, Pagnini I, Simonini G. A systematic review on biological therapies in juvenile idiopathic inflammatory myopathies: An evidence gap in precision medicine. Clin Exp Rheumatol. 2022;40(2):457-470. doi:10.55563/clinexprheumatol/ltrj4l; Каледа МИ, Никишина ИП, Николаева ЕВ, Шаповаленко АН, Федоров ЕС, Пачкория ТН. Ритуксимаб при ревматических заболеваниях у детей: результаты ретроспективного исследования безопасности терапии. Научно-практическая ревматология. 2021;59(2):208-214. doi:10.47360/1995-4484-2021-208-214; Насонов ЕЛ, Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-383. doi:10.47360/1995-4484-2021-367-383; Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020;79(10):1340-1348. doi:10.1136/annrheumdis-2020-217101; Curiel RV, Nguyen W, Mamyrova G, Jones D, Ehrlich A, Brindle KA, et al.; Abatacept in Dermatomyositis (AID) Trial Investigators. Improvement in disease activity in refractory juvenile dermatomyositis following abatacept therapy. Arthritis Rheumatol. 2023;75(7):1229-1237. doi:10.1002/art.42450; Kalampokis I, Yi BY, Smidt AC. Abatacept in the treatment of localized scleroderma: A pediatric case series and systematic literature review. Semin Arthritis Rheum. 2020;50(4):645-656. doi:10.1016/j.semarthrit.2020.03.020; Adrovic A, Yildiz M, Haslak F, Koker O, Aliyeva A, Sahin S, et al. Tocilizumab therapy in juvenile systemic sclerosis: a retrospective single centre pilot study. Rheumatol Int. 2021;41(1):121-128. doi:10.1007/s00296-020-04732-z; Pin A, Tesser A, Pastore S, Moressa V, Valencic E, Arbo A, et al. Biological and clinical changes in a pediatric series treated with off-label JAK inhibitors. Int J Mol Sci. 2020;21(20):7767. doi:10.3390/ijms21207767; Chuprin J, McCormack L, Richmond JM, Rashighi M. Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: An update. Expert Rev Clin Immunol. 2022;18(3):263-272. doi:10.1080/1744666X.2022.2047022; https://rsp.mediar-press.net/rsp/article/view/3469

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/3469
https://doi.org/10.47360/1995-4484-2023-639-649

المؤلفون: M. I. Kaleda, Z. A. Kolkhidova, I. P. Nikishina, М. И. Каледа, З. А. Колхидова, И. П. Никишина

المساهمون: Исследование проводилось в рамках выполнения фундаментального научного исследования по теме «Выявление клинических фенотипов и прогнозирование вариантов течения аутоиммунных и аутовоспалительных ревматических заболеваний детского возраста» FURS-2022-0001 (регистрационный номер в ЕГИСУ 1021051302580-4).

المصدر: Rheumatology Science and Practice; Vol 61, No 3 (2023); 369-376 ; Научно-практическая ревматология; Vol 61, No 3 (2023); 369-376 ; 1995-4492 ; 1995-4484

مصطلحات موضوعية: детский возраст, biologics, JADI damage index, rheumatoid factor, childhood, генно-инженерные биологические препараты, индекс повреждения JADI, ревматоидный фактор

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3365/2293; Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767-778. doi:10.1016/S0140-6736(07)60363-8; Saurenmann RK, Rose JB, Tyrrell P, Feldman BM, Laxer RM, Schneider R, et al. Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: Ethnicity as a risk factor. Arthritis Rheum. 2007;56(6):1974-1984. doi:10.1002/art.22709; Demirkaya E, Ozen S, Bilginer Y, Ayaz NA, Makay BB, Unsal E, et al. The distribution of juvenile idiopathic arthritis in the eastern Mediterranean: Results from the registry of the Turkish Paediatric Rheumatology Association. Clin Exp Rheumatol. 2011;29(1):111-116.; Horneff G, Borchert J, Heinrich R, Kock S, Klaus P, Dally H, et al. Incidence, prevalence, and comorbidities of juvenile idiopathic arthritis in Germany: A retrospective observational cohort health claims database study. Pediatr Rheumatol Online J. 2022;20(1):100. doi:10.1186/s12969-022-00755-x; Mahmud SA, Binstadt BA. Autoantibodies in the pathogenesis, diagnosis, and prognosis of juvenile idiopathic arthritis. Front Immunol. 2019;9:3168. doi:10.3389/fimmu.2018.03168; Davies R, Gaynor D, Hyrich KL, Pain CE. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review. Semin Arthritis Rheum. 2017;46(5):584-593. doi:10.1016/j.semarthrit.2016.10.008; Lipinska J, Lipinska S, Kasielski M, Smolewska E. Anti-MCV and anti-CCP antibodies-diagnostic and prognostic value in children with juvenile idiopathic arthritis (JIA). Clin Rheumatol. 2016;35(11):2699-2706. doi:10.1007/s10067-016-3355-1; Petty RE, Laxer RM, Lindsley CB, Wedderburn LR (eds). Textbook of pediatric rheumatology. Philadelphia, PA:Elsiever Saunders;2016.; Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G, et al.; ReACCh-Out investigators. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis. 2015;74(10):1854-1860. doi:10.1136/annrheumdis-2014-205372; Otten MH, Anink J, Prince FH, Twilt M, Vastert SJ, ten Cate R, et al. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register. Ann Rheum Dis. 2015;74(7):1379-1386. doi:10.1136/annrheumdis-2013-204641; Shepherd J, Cooper K, Harris P, Picot J, Rose M. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: A systematic review and economic evaluation. Health Technol Assess. 2016;20(34):1-222. doi:10.3310/hta20340; Horneff G, Klein A, Klotsche J, Minden K, Huppertz HI, WellerHeinemann F, et al. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther. 2016;18(1):272. doi:10.1186/s13075-016-1170-3; Martini A, Ravelli A, Avcin T, Beresford MW, Burgos-Vargas R, Cuttica R, et al.; Pediatric Rheumatology International Trials Organization (PRINTO). Toward new classification criteria for juvenile idiopathic arthritis: First steps, pediatric rheumatology international trials organization international consensus. J Rheumatol. 2019;46(2):190-197. doi:10.3899/jrheum.180168; Viola S, Felici E, Magni-Manzoni S, Pistorio A, Buoncompagni A, Ruperto N, et al. Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum. 2005;52(7):2092-2102. doi:10.1002/art.21119; Koopman-Keemink Y, van Rossum MA, Wulffraat NM, van Suijlekom-Smit LW. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: Results of the Dutch national Arthritis and Biologics in Children Register. Ann Rheum Dis. 2015;74(7):1379-1386. doi:10.1136/annrheumdis-2013-204641; Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O’Neil KM, Zeft AS, et al.; Childhood Arthritis and Rheumatology Research Alliance (CARRA). Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: Time to achievement, total duration, and predictors. J Rheumatol. 2014;41(6):1163-1170. doi:10.3899/jrheum.131503; Yamasaki Y, Nakamura A, Kubota T, Mitsunobu T, Moriyama M, Takei S, et al. Rheumatoid factor value for determining the first biologic agent to use for non-systemic juvenile idiopathic arthritis. Mod Rheumatol. 2022 Oct 5:roac125. doi:10.1093/mr/roac125; Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: Therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Rheumatol. 2019;71(6):846-863. doi:10.1002/art.40884; Oliveira-Ramos F, Eusébio M, Martins F, Mourão AF, Furtado C, Campanilho-Marques R, et al. Juvenile idiopathic arthritis in adulthood: Fulfilment of classification criteria for adult rheumatic diseases, long-term outcomes and predictors of inactive disease, functional status and damage. RMD Open. 2016;2(2):e000304. doi:10.1136/rmdopen-2016-000304; Oen K, Guzman J, Dufault B, Tucker LB, Shiff NJ, Duffy KW, et al.; the Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh-Out) investigators. Health-related quality of life in an inception cohort of children with juvenile idiopathic arthritis: A longitudinal analysis. Arthritis Care Res (Hoboken). 2018;70(1):134-144. doi:10.1002/acr.23236; Guzman J, Henrey A, Loughin T, Berard RA, Shiff NJ, Jurencak R, et al.; ReACCh-Out Investigators. Predicting which children with juvenile idiopathic arthritis will not attain early remission with conventional treatment: Results from the ReACCh-Out cohort. J Rheumatol. 2019;46(6):628-635. doi:10.3899/jrheum.180456; Montag LJ, Horneff G, Hoff P, Klein A, Kallinich T, Foeldvari I, et al. Medication burden in young adults with juvenile idiopathic arthritis: Data from a multicentre observational study. RMD Open. 2022;8(2):e002520. doi:10.1136/rmdopen-2022-002520; Berthold E, Månsson B, Kahn R. Outcome in juvenile idiopathic arthritis: A population-based study from Sweden. Arthritis Res Ther. 2019;21(1):218. doi:10.1186/s13075-019-1994-8; Юношеский артрит у детей URL: https://aspirre-russia.ru/upload/medialibrary/2d7/%D0%9C08.0%20%D0%AE%D0%BD%D0%BE%D1%88%D0%B5%D1%81%D0%BA%D0%B8%D0%B9%20%D0%B0%D1%80%D1%82%D1%80%D0%B8%D1%82%20%D1%83%20%D0%B4%D0%B5%D1%82%D0%B5%D0%B9.pdf (Accessed: DD Month 2023).; Каледа МИ, Никишина ИП, Николаева ЕВ, Шаповаленко АН, Федоров ЕС, Пачкория ТН. Ритуксимаб при ревматических заболеваниях у детей: результаты ретроспективного исследования безопасности терапии. Научно-практическая ревматология. 2021;59(2):208-214. doi:10.47360/1995-4484-2021-208-214; Kearsley-Fleet L, Sampath S, McCann LJ, Baildam E, Beresford MW, Davies R, et al. Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom. Rheumatology (Oxford). 2019;58(2):331-335. doi:10.1093/rheumatology/key306; Romano M, Pontikaki I, Gattinara M, Ardoino I, Donati C, Boracchi P, et al. Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients. Reumatismo. 2014;65(6):278-285. doi:10.4081/reumatismo.2013.682; Syed RH, Gilliam BE, Moore TL. Rheumatoid factors and anticyclic citrullinated peptide antibodies in pediatric rheumatology. Curr Rheumatol Rep. 2008;10(2):156-163. doi:10.1007/s11926-008-0027-4; Adrovic A, Yildiz M, Köker O, Şahin S, Barut K, Kasapçopur Ö. Biologics in juvenile idiopathic arthritis-main advantages and major challenges: A narrative review. Arch Rheumatol. 2020; 36(1):146-157. doi:10.46497/ArchRheumatol.2021.7953; https://rsp.mediar-press.net/rsp/article/view/3365

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/3365
https://doi.org/10.47360/1995-4484-2023-369-376

المؤلفون: Shakhbanov R.R., Shishkin I.A., Efremenkov A.M., Kirgizov I.V., Zykin A.P.

المصدر: Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care; Vol 13 (2023): Supplement; 205 ; Российский вестник детской хирургии, анестезиологии и реаниматологии; Vol 13 (2023): Supplement; 205 ; 2587-6554 ; 2219-4061 ; 10.17816/psaic.2023

مصطلحات موضوعية: дети, детский возраст, пилонидальная киста, эпителиальный копчиковый ход, пилонидальный синус

وصف الملف: application/pdf

Relation: https://rps-journal.ru/jour/article/view/1760/1723; https://rps-journal.ru/jour/article/view/1760

الاتاحة: https://rps-journal.ru/jour/article/view/1760

المؤلفون: Davlyatov S.B., Pulotov K.D., Rofiev R.R., Bakhodurov D.T.

المصدر: Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care; Vol 13 (2023): Supplement; 44 ; Российский вестник детской хирургии, анестезиологии и реаниматологии; Vol 13 (2023): Supplement; 44 ; 2587-6554 ; 2219-4061 ; 10.17816/psaic.2023

مصطلحات موضوعية: пищевод, послеожоговые стриктуры, бужирование, детский возраст

وصف الملف: application/pdf

Relation: https://rps-journal.ru/jour/article/view/1612/1575; https://rps-journal.ru/jour/article/view/1612

الاتاحة: https://rps-journal.ru/jour/article/view/1612

المؤلفون: A. R. Khaibullina, F. A. Khabirov, T. I. Khaibullin, А. Р. Хайбуллина, Ф. А. Хабиров, Т. И. Хайбуллин

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 15 (2023): (Suppl. 1); 22-25 ; Неврология, нейропсихиатрия, психосоматика; Vol 15 (2023): (Suppl. 1); 22-25 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-0

مصطلحات موضوعية: детский возраст, differential diagnosis, childhood, дифференциальная диагностика

وصف الملف: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/2074/1570; Hawton A, Goodwin E, Boddy K, et al. Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years. Mult Scler. 2022 Mar;28(3):346-51. doi:10.1177/1352458520954172. Epub 2020 Sep 3.; Wallin MT, Culpepper WJ, Campbell JD, et al; US Multiple Sclerosis Prevalence Workgroup. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology. 2019 Mar 5;92(10):e1029- e1040. doi:10.1212/WNL.0000000000007035. Epub 2019 Feb 15. Erratum in: Neurology. 2019 Oct 8;93(15):688.; Бойко АН, Хабиров ФА, Хайбуллин ТИ. Рассеянный склероз: краткое руководство для практического врача. 4-е изд., испр. и доп. Казань: ИД «МедДоК»; 2020. 116 с.; Клинические рекомендации «Рассеянный склероз», 2022. Доступно по ссылке: https://cr.minzdrav.gov.ru/schema/739_ Сlinical guidelines for multiple sclerosis, 2022.Available from: https://cr.minzdrav.gov.ru/schema/739_ (In Russ.).; Wong YYM, de Mol CL, van der Vuurst de Vries RM, et al. Real-world validation of the 2017 McDonald criteria for pediatric MS. Neurol Neuroimmunol Neuroinflamm. 2018 Dec 14;6(2):e528. doi:10.1212/NXI.0000000000000528; Fadda G, Brown RA, Longoni G, et al; Canadian Pediatric Demyelinating Disease Network. MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. Lancet Child Adolesc Health. 2018 Mar;2(3):191-204. doi:10.1016/S2352-4642(18)30026-9. Epub 2018 Feb 1.; Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-73. doi:10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21.; Alroughani R, Boyko A. Pediatric multiple sclerosis: a review. BMC Neurol. 2018 Mar 9;18(1):27. doi:10.1186/s12883-018-1026-3; Бойко АН, Быкова ОВ, Сиверцева СА. Рассеянный склероз у детей и подростков: клиника, диагностика, лечение. Москва: Изд-во «Медицинское информационное агентство»; 2016. 408 с.; Chabas D, Castillo-Trivino T, Mowry EM, et al. Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype? Neurology. 2008 Sep 30;71(14):1090-3. doi:10.1212/01.wnl.0000326896.66714.ae; Jakimovski D, Awan S, Eckert SP, et al. Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment. CNS Drugs. 2022 Jan;36(1):45-59. doi:10.1007/s40263-021-00887-w. Epub 2021 Dec 23.; Vishwas MS, Chitnis T, Pienaar R, et al. Tract-based analysis of callosal, projection, and association pathways in pediatric patients with multiple sclerosis: a preliminary study. AJNR Am J Neuroradiol. 2010 Jan;31(1):121-8. doi:10.3174/ajnr.A1776. Epub 2009 Oct 22.; Banwell B, Arnold DL, Tillema JM, et al. MRI in the evaluation of pediatric multiple sclerosis. Neurology. 2016 Aug 30;87(9 Suppl 2):S88-96. doi:10.1212/WNL.0000000000002787; Chabas D, Ness J, Belman A, et al; US Network of Pediatric MS Centers of Excellence. Younger children with MS have a distinct CSF inflammatory profile at disease onset. Neurology. 2010 Feb 2;74(5):399-405. doi:10.1212/WNL.0b013e3181ce5db0; De Meo E, Meani A, Moiola L, et al. Dynamic gray matter volume changes in pediatric multiple sclerosis: A 3.5 year MRI study. Neurology. 2019 Apr 9;92(15):e1709-e1723. doi:10.1212/WNL.0000000000007267. Epub 2019 Mar 13.; Бембеева РЦ, Пилия СВ, Волкова ЭЮ. Рассеянный склероз у детей. Режим доступа: https://www.lvrach.ru/2007/07/4535460; Nohejlova H, Kayserova J, Capek V, et al. Paediatric onset of multiple sclerosis: Analysis of chemokine and cytokine levels in the context of the early clinical course. Mult Scler Relat Disord. 2020 Nov;46:102467. doi:10.1016/j.msard.2020.102467. Epub 2020 Aug 24.; https://nnp.ima-press.net/nnp/article/view/2074

الاتاحة: https://nnp.ima-press.net/nnp/article/view/2074
https://doi.org/10.14412/2074-2711-2023-1S-22-25

المؤلفون: A. P. Mazaev, M. S. Molodtsov, S. P. Shchelykalina, А. П. Мазаев, М. С. Молодцов, С. П. Щелыкалина

المساهمون: The work was performed at the Morozov Children's City Clinical Hospital of the Department of Health of Moscow, 1, 4th Dobryninsky per., Moscow 119049, Russian Federation., Работа выполнена в ГБУЗ “Морозовская детская городская клиническая больница Департамента здравоохранения города Москвы”, 119049 Москва, 4-й Добрынинский пер., д. 1, Российская Федерация.

المصدر: Medical Visualization; Том 28, № 1 (2024); 21-34 ; Медицинская визуализация; Том 28, № 1 (2024); 21-34 ; 2408-9516 ; 1607-0763

مصطلحات موضوعية: МРТ, intracerebral hemorrhage, childhood, MRI, внутримозговое кровоизлияние, детский возраст

وصف الملف: application/pdf

Relation: https://medvis.vidar.ru/jour/article/view/1373/853; https://medvis.vidar.ru/jour/article/downloadSuppFile/1373/2154; https://medvis.vidar.ru/jour/article/downloadSuppFile/1373/2155; https://medvis.vidar.ru/jour/article/downloadSuppFile/1373/2169; https://medvis.vidar.ru/jour/article/downloadSuppFile/1373/2170; Щедеркина И.О., Заваденко Н.Н., Колтунов И.Е. Инсульт у детей и подростков: формирование педиатрического регистра. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016; 9: 24–29. http://doi.org/10.17116/jnevro20161169124-29; Boulouis G., Blauwblomme T., Hak J.F. et al. Nontraumatic Pediatric Intracerebral Hemorrhage. Stroke. 2019; 50 (12): 3654–3661. http://doi.org/10.1161/STROKEAHA.119.025783; Mackay M., Kirton A., deVeber G. Swaiman’s pediatric neurology. 6th ed / Swaiman K. (ed.). Elsevier, 2017. 1308 p.; Львова О.А., Кузнецов Н.Н., Гусев В.В., Вольхина С.А. Эпидемиология и этиология инсультов у детей грудного возраста. Неврология, нейропсихиатрия, психосоматика. 2013. Спецвыпуск 2: 50–55.; Boulouis G., Stricker S., Benichi S. et al. Etiology of intracerebral hemorrhage in children: cohort study, systematic review, and meta-analysis. J. Neurosurg. Pediatr. 2021; 27 (3): 357–363. http://doi.org/10.3171/2020.7.PEDS20447; Хачатуров Ю.А., Щедеркина И.О., Плавунов Н.Ф., Сидоров А.М., Петряйкина Е.Е., Витковская И.П., Кадышев В.А. Инсульт у детей и подростков: актуальные проблемы догоспитальной диагностики. Архивъ внутренней медицины. 2020; 10 (1): 21–30. https://doi.org/10.20514/2226-6704-2020-10-1-21-30; Bradley W.G. Jr. MR appearance of hemorrhage in the brain. Radiology. 1993; 189 (1): 15–26. http://doi.org/10.1148/radiology.189.1.8372185; Kidwell C.S., Wintermark M. Imaging of intracranial haemorrhage. Lancet Neurol. 2008; 7 (3): 256–267. http://doi.org/10.1016/S1474-4422(08)70041-3; Terayama Y., Tanahashi N., Fukuuchi Y., Gotoh F. Prognostic value of admission blood pressure in patients with intracerebral hemorrhage. Keio Cooperative Stroke Study. Stroke. 1997; 28 (6): 1185–1188. http://doi.org/10.1161/01.str.28.6.1185; Urday S., Kimberly W.T., Beslow L.A. et al. Targeting Secondary Injury in Intracerebral Haemorrhage–Perihaematomal Oedema. Nat. Rev. Neurol. 2015; 11 (2): 111–122. http://doi.org/10.1038/nrneurol.2014.264; Chen Y., Chen S., Chang J. et al. Perihematomal Edema After Intracerebral Hemorrhage: An Update on Pathogenesis, Risk Factors, and Therapeutic Advances. Front. Immunol. 2021; 12: 740632. http://doi.org/10.3389/fimmu.2021.740632; Khalaf A., Iv M., Fullerton H., Wintermark M. Pediatric Stroke Imaging. Pediatr. Neurol. 2018; 86: 5–18. http://doi.org/10.1016/j.pediatrneurol.2018.05.008; Anzalone N., Scotti R., Riva R. Neuroradiologic differential diagnosis of cerebral intraparenchymal hemorrhage. Neurol. Sci. 2004; 25, Suppl. 1: S3–5. http://doi.org/10.1007/s10072-004-0205-8; Ryan M.E., Jaju A., Ciolino J.D., Alden T. Rapid MRI evaluation of acute intracranial hemorrhage in pediatric head trauma. Neuroradiology. 2016; 58 (8): 793–799. http://doi.org/10.1007/s00234-016-1686-x; Mehta H., Acharya J., Mohan A.L. et al. Minimizing Radiation Exposure in Evaluation of Pediatric Head Trauma: Use of Rapid MR Imaging. Am. J. Neuroradiol. 2015; 37 (1): 11–18. http://doi.org/10.3174/ajnr.a4464; Федоров М.А., Диомидова В.Н., Мигушкина Л.П. Исследование диагностической эффективности магнитно-резонансной томографии при геморрагическом инсульте. Медицинский альманах. 2016; 5 (45): 115–119.; Hillal A., Ullberg T., Ramgren B., Wassélius J. Computed tomography in acute intracerebral hemorrhage: neuroimaging predictors of hematoma expansion and outcome. Insights. Imaging. 2022; 13 (1): 180. http://doi.org/10.1186/s13244-022-01309-1; Goldman-Yassen A.E., Dehkharghani S. Neuroimaging in Pediatric Stroke and Cerebrovascular Disease. Stroke. Dehkharghani S (Ed.). Exon Publications, Brisbane, Australia. ISBN: 978-0-6450017-6-1. https://doi.org/10.36255/exonpublications.stroke.2021; Lee S., Jiang B., Heit J.J. et al. Cerebral Perfusion in Pediatric Stroke: Children Are Not Little Adults. Top. Magn. Reson. Imaging. 2021; 30 (5): 245–252. http://doi.org/10.1097/RMR.0000000000000275; Pluncevic Gligoroska J., Gontarev S., Dejanova B. et al. Red Blood Cell Variables in Children and Adolescents regarding the Age and Sex. Iran J. Public. Health. 2019; 48 (4): 704–712. PMID: 31110981; Macellari F., Paciaroni M., Agnelli G., Caso V. Neuroimaging in Intracerebral Hemorrhage. Stroke. 2014; 45 (3): 903–908. http://doi.org/10.1161/strokeaha.113.003701; Kang B.K., Na D.G., Ryoo J.W. et al. Diffusion-weighted MR imaging of intracerebral hemorrhage. Korean J. Radiol. 2001; 2 (4): 183–191. http://doi.org/10.3348/kjr.2001.2.4.183; Mendelow A.D., Gregson B.A., Rowan E.N. et al. Early Surgery Versus Initial Conservative Treatment in Patients With Spontaneous Supratentorial Lobar Intracerebral Haematomas (STICH II): A Randomised Trial. Lancet. 2013; 382 (9890): 397–408. http://doi.org/10.1016/S0140-6736(13)60986-1; Mendelow A.D., Gregson B.A., Fernandes H.M. et al. Early Surgery Versus Initial Conservative Treatment in Patients With Spontaneous Supratentorial Intracerebral Haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): A Randomised Trial. Lancet. 2005; 365 (9457): 387–397. http://doi.org/10.1016/S0140-6736(05)17826-X; Mould W.A., Carhuapoma J.R., Muschelli J. et al. Minimally Invasive Surgery Plus Recombinant Tissue-Type Plasminogen Activator for Intracerebral Hemorrhage Evacuation Decreases Perihematomal Edema. Stroke. 2013; 44 (3): 627–634. http://doi.org/10.1161/STROKEAHA.111.000411; Li N., Worthmann H., Heeren M. et al. Temporal Pattern of Cytotoxic Edema in the Perihematomal Region After Intracerebral Hemorrhage: A Serial Magnetic Resonance Imaging Study. Stroke. 2013; 44 (4): 1144–1146. http://doi.org/10.1161/strokeaha.111.000056; Kim-Han J.S., Kopp S.J., Dugan L.L., Diringer M.N. Perihematomal mitochondrial dysfunction after intracerebral hemorrhage. Stroke. 2006; 37 (10): 2457–2462. http://doi.org/10.1161/01.STR.0000240674.99945.4e. Epub 2006 Sep 7. Erratum in: Stroke. 2006; 37 (12): 3057. PMID: 16960094; Губский Л.В., Анисимов Н.В., Шамалов Н.А., Скворцова В.И. Диагностика нетравматических внутричерепных кровоизлияний методами КТ и МРТ. В кн.: Геморрагический инсульт / Под ред. В.И. Скворцовой, В.В. Крылова. М.: ГЭОТАР-Медиа, 2005: 38–59.; Араблинский А.В. Дифференциальная диагностика нетравматических острых заболеваний головного мозга в условиях приемного отделения с использованием КТ и МРТ. REJR. 2020; 10 (4): 60–74. http://doi.org/10.21569/2222-7415-2020-10-4-6074; https://medvis.vidar.ru/jour/article/view/1373

الاتاحة: https://medvis.vidar.ru/jour/article/view/1373
https://doi.org/10.24835/1607-0763-1373

المؤلفون: T. A. Vladimirova, A. S. Martynova, Т. Ю. Владимирова, А. Б Мартынова

المصدر: Meditsinskiy sovet = Medical Council; № 19 (2023); 88-95 ; Медицинский Совет; № 19 (2023); 88-95 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: Имудон, topical bacterial lysates, childhood, recurrent respiratory diseases, IRS-19, Imudon, топические бактериальные лизаты, детский возраст, рецидивирующие заболевания органов дыхания, ИРС19

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7905/7021; Pereira L, Monyror J, Almeida FT, Almeida FR, Guerra E, Flores-Mir C, Pachêco-Pereira C. Prevalence of adenoid hypertrophy: A systematic review and meta-analysis. Sleep Medicine Reviews. 2018;38:101–112. https://doi.org/10.1016/j.smrv.2017.06.001.; Синева ЕЛ, Панкова ВБ, Саранча ЕО. Распространенность и структура заболеваний ЛОР-органов у детей промышленных регионов. Вестник оториноларингологии. 2015;80(2):48–52. https://doi.org/10.17116/otorino201580248-52.; Тюркина СИ, Минасян ВС, Савенкова МС, Китайгородский АП, Овечкина НВ, Кац ТГ, Лапшина ТА. Лечение и профилактика аденоидитов бактериальными лизатами у часто болеющих детей. Детские инфекции. 2013;12(1):26–30. Режим доступа: https://detinf.elpub.ru/jour/article/view/105.; Соломай ТВ, Семененко ТА, Ильина НИ. Обоснование стратегии неспецифической иммунопрофилактики активной ВЭБ-инфекции. Иммунология. 2021;42(6):686–696. https://doi.org/10.33029/0206-4952-2021-42-6-686-696.; Özdaş T, Özdaş S, Babademez MA, Muz SE, Atilla H, Baştimur S et al. Significant association between SCGB1D4 gene polymorphisms and susceptibility to adenoid hypertrophy in a pediatric population. Turk J Med Sci. 2017;47(1):201–210. https://doi.org/10.3906/sag-1512-93.; Atilla MH, Özdaş S, Özdaş T, Baştimur S, Muz SE, Öz I, Kurt K et al. Association of Ugrp2 gene polymorphisms with adenoid hypertrophy in the pediatric population. Braz J Otorhinolaryngol. 2018;84(5):599–607. https://doi.org/10.1016/j.bjorl.2017.07.004.; Zuo L, He L, Huang A, Liu Y, Zhang A, Wang L et al. Risk factors and antibiotic sensitivity of aerobic bacteria in Chinese children with adenoid hypertrophy. BMC Pediatrics. 2022;22(1):553. https://doi.org/10.1186/s12887-022-03613-7.; Kania R, Vironneau P, Dang H, Bercot B, Cambau E, Verillaud B et al. Bacterial biofilm in adenoids of children with chronic otitis media. Part I: a case control study of prevalence of biofilms in adenoids, risk factors and middle ear biofilms. Acta Otolaryngol. 2019;139(4):345–350. https://doi.org/10.1080/00016489.2019.1571282.; Evcimik MF, Dogru M, Cirik AA, Nepesov MI. Adenoid hypertrophy in children with allergic disease and influential factors. Int J Pediatr Otorhinolaryngol. 2015;79(5):694–697. https://doi.org/10.1016/j.ijporl.2015.02.017.; Dogru M, Evcimik MF, Calim OF. Does adenoid hypertrophy affect disease severity in children with allergic rhinitis? Eur Arch Otorhinolaryngol. 2017;274(1):209–213. https://doi.org/10.1007/s00405-016-4196-x.; Lou Z. Adenoid hypertrophy in children and allergic rhinitis. Eur Arch Otorhinolaryngol. 2018;275(3):831–832. https://doi.org/10.1007/s00405017-4737-y.; Лихачев АГ. Справочник по оториноларингологии. М.: Медицина; 1967. 326 с.; Пальчун ВТ, Лучихин ЛА, Магомедов ММ. Оториноларингология. М.: ГЭОТАР-Медиа; 2016. 584 с.; Карпова ЕП, Тулупов ДА, Карнеева ОВ, Поляков ДП. Гипертрофия адено­ идов. Гипертрофия небных миндалин: клинические рекомендации. М.; 2021. 49 с. Режим доступа: http://otolar-centre.ru/images/2022/Clinical/%D0%93%D0%B8%D0%BF%D0%B5%D1%80%D1%82%D1%80%D0%BE%D1%84%D0%B8%D1%8F_%D0%B0%D0%B4%D0%B5%D0%BD%D0%BE%D0%B8%D0%B4%D0%BE%D0%B2.pdf.; Гаращенко ТИ, Гаращенко МВ, Овечкина НВ, Кац ТГ. Клинико-иммунологическая эффективность Имудона у часто и длительно болеющих детей с патологией лимфоглоточного кольца. Педиатрия. Журнал имени Г.Н. Сперанского. 2009;88(5):98–104. Режим доступа: https://pediatriajournal.ru/archive?show=300&section=2498.; Шахов АВ, Красильникова СВ. Эффективность топических бактериальных лизатов при воспалительных заболеваниях полости рта и глотки. Медицин­ ский совет. 2023;17(7):20–25. https://doi.org/10.21518/ms2023-114.; Долбова СИ, Дмитриева НВ, Ткаченко ТГ, Гудков РА. Эффективность имудона и ИРС-19 для профилактики заболеваний у детей в дошкольных учреждениях. Педиатрическая фармакология. 2005;2(S):69. Режим доступа: https://elibrary.ru/pwhbtz.; Гаращенко ТИ. Бактериальные лизаты для местного применения в профилактике и лечении хронических аденоидитов у детей. Вопросы современной педиатрии. 2007;6(1):92–96. Режим доступа: https://vsp.sprjournal.ru/jour/article/view/1003.; Рязанцев СВ, Тихомирова ИА. Хронические заболевания лор-органов у детей: дифференциальные схемы лечения и профилактики обострений. Вопросы современной педиатрии. 2009;8(1):125–129. Режим доступа: https://vsp.spr-journal.ru/jour/article/view/1049.; Заплатников АЛ, Гирина АА, Бурцева ЕИ, Леписева ИВ, Майкова ИД, Свинцицкая ВИ. Острые, рекуррентные и рецидивирующие инфекции респираторного тракта у детей: вопросы иммунопрофилактики и иммунотерапии. РМЖ. Мать и дитя. 2023;6(1):50–59. https://doi.org/10.32364/2618-8430-2023-6-1-50-59.; Савенкова МС. Опыт применения бактериальных лизатов в клинической практике педиатра и оториноларинголога. Вестник оториноларин­ гологии. 2012;77(5):73–77. Режим доступа: https://www.mediasphera.ru/issues/vestnik-otorinolaringologii/2012/5/030042-46682012518.; Гаращенко ТИ, Володарская ВГ. Смесь лизатов бактерий для топического применения в профилактике и лечении хронического тонзиллит у детей. Вопросы современной педиатрии. 2009;8(6):109–112. Режим доступа: https://vsp.spr-journal.ru/jour/article/view/1203.; Безрукова ЕВ, Воробейчиков ЕВ, Конусова ВГ, Сосунов АВ, Шамцян ММ, Артюшкин СА, Симбирцев АС. Применение иммунопрепаратов для лечения острого вирусного назофарингита. Медицинская иммунология. 2021;23(5):1151–1164. https://doi.org/10.15789/1563-0625-EOI-2300. 0.; Свистушкин ВМ, Никифорова ГН, Золотова АВ, Степанова ВА. Применение топических бактериальных лизатов в современной клинической практике Медицинский совет. 2021;(6):49–56. https://doi.org/10.21518/ 2079-701X-2021-6-49-56.; https://www.med-sovet.pro/jour/article/view/7905

الاتاحة: https://www.med-sovet.pro/jour/article/view/7905
https://doi.org/10.21518/ms2023-371